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ABSTRACT 
 
 
ACCURATE MUTATION ANNOTATION AND FUNCTIONAL PREDICTION 
ENHANCE THE APPLICABILITY OF -OMICS DATA IN PRECISION MEDICINE  
 
Tenghui Chen, M.S. 
Advisory Professor: Ken Chen, Ph.D. 
 
 
 
        Clinical sequencing has been recognized as an effective approach for 
enhancing the accuracy and efficiency of cancer patient management and therefore 
achieve the goals of personalized therapy. However, the accuracy of large scale 
sequencing data in clinics has been constrained by many different aspects, such as 
clinical detection, annotation and interpretation of the variants that are observed in 
clinical sequencing data. In my Ph.D thesis work, I mainly investigated how to 
comprehensively and efficiently apply high dimensional -omics data to enhance the 
capability of precision cancer medicine. Following this motivation, my dissertation 
has been focused on two important topics in translational genomics. 
  
      1) Developing a computational approach to resolve ambiguities in existing 
clinical genomic annotations and to facilitate correct diagnostic and treatment 
decisions. I have developed a multi-level variant annotator, TransVar, to perform 
precise annotation at genomic, mRNA and protein levels. TransVar implements 
three main functions: 1) it performs an innovative “reverse annotation” function, 
which identifies the genomic variants that can be translated into a given protein 
	  vii	  
variant through alternative splicing. This function significantly improves the accuracy 
of genomic testing in clinics and functional validation in genomic laboratories; 2) It 
performs “equivalence annotation”, which identifies the protein variants having 
identical genomic origins with a given protein variant. This function resolves 
annotation inconsistencies among variants imported from different data sources, and 
is crucial for precise mutation biomarker identification and functional prediction; 3) It 
improves “forward annotation” (i.e., translation of genomic variants to protein 
variants) over existing annotators by more rigorously implementing the Human 
Genome Variation Society (HGVS) nomenclature. Our study also tried to illustrate 
the ambiguities of annotation among different transcript databases and different 
mutation types. TransVar standardizes mutation annotation and enables precise 
characterization of genomic variants in the context of functional genomic studies and 
clinical decision support and will significantly advance genomic medicine. 
 
        2) Developing a statistical framework to precisely identify hotspot mutations and 
investigate their functional impact on tumorigenesis and drug therapeutic response 
using large-scale -omics data. I have proposed a statistical model, which utilizes 
characteristics of genomic data to nominate 702 cancer type-specific hotspot 
mutations in 549 genes. It models background mutation rate variations among 
different genes, mutation subtypes and di-nucleotide sequence contexts and 
effectively identifies hotspots that have more than the expected number of recurrent 
mutations. We then investigate the mutational signatures represented by the hotspot 
mutations and find they vary from one tumor type to another, suggesting distinct 
	  viii	  
mutational positive selections during different cancer progressions. In addition, we 
build an integrative statistical framework by using transcriptomics, proteomics and 
pharmacogenomics data to investigate the diverse functions of each hotspot 
mutation under different disease and biological contexts and to associate the effects 
of mutations on RNA/protein expression, pathway activity, and drug sensitivity. We 
not only validate diverse functions of well-known hotspot mutations in different 
contexts, but also identify some novel hotspot mutations such as MAP3K4 A1199 
deletion, NR1H2 R175 insertion, and GATA3 P409 insertion with different functional 
associations. Our study addresses a long-term challenge of explicitly distinguishing 
driver mutations from passengers, and nominates a set of putative driver mutations 
that possess diverse functional potentials.  
 
        The translational genomics research I conducted in my Ph.D study will benefit 
the cancer research community. The tools I developed will answer translational 
genomics questions such as identification of biomarkers for clinical diagnostics and 
treatment, and promote our understanding of the biological function of driver 
mutations towards the realization of personalized medicine. 
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1.1 Application of next generation sequencing (NGS) data in personalized 
medicine 
1.1.1 Impact of NGS techniques on human health 
         Starting from the 1970’s, DNA sequencing techniques have continuously 
revolutionized our understanding of the human genome and enhanced our capability 
for learning biological principles from human genetics. The development of 
sequencing technologies originated from the pioneer works of Walter Gilbert [1] and 
Frederick Sanger [2]. After that, DNA sequencing technology continuously improved 
in terms of both instruments and mechanics to advance the generality and accuracy 
with which we understand human genome. In 2001, the human genome project 
(HGP) [3] was finished, which enabled us to have a close look at the human genetic 
codes for the first time and prompted the potential of examining different diseases in 
a personalized revolution. The achievements of the HGP lie in several aspects: 1) It 
gave a hint that people could actually utilize the genetic information to improve the 
understanding of disease susceptibilities and indications of disease prevention; 2) It 
involved the collaborations of multiple research institutes such as the Sanger 
Institute and the biotech industries, and increased the possibility of transferring 
human genetic research into business and in turn helping better monitor human 
health; 3) Most importantly, it let people believe that the era of personalized 
medicine is not far away, and comprehensively improved the clinical diagnostics and 
drug development using human genetic information. 
        After the HGP, which represented the 1st generation sequencing technology, 
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multiple 2nd generation sequencing technologies have emerged (Table 1.1), such as 
454 sequencing (http://www.my454.com), Solexa/Illumina (http://www.illumina.com), 
SOLiD (http://www. appliedbiosystems.com), and Polonator (http://www. 
polonator.org). Each technology had its own advantages and weaknesses. Thanks 
to the development of those technologies, we have been able to continuously 
understand the human health based on genetics and dramatically reduce the cost of 
sequencing from more than 100,000 dollars per genome to a few thousand dollars. 
These are important for making DNA sequencing more applicable and useful, as it 
becomes affordable to individuals and allows people to infer more health related 
indications based on genetic information. 
Table 1.1 Popular 2nd generation sequencing technologies in the market 
Sequencing 
platform 
Sequencing 
chemistry Read length 
Template 
preparation Application 
Roche 454 Pyrosequencing 400bp Emulsion PCR 
WGS and WES of 
microbes 
Illumina 
Hiseq 3000 
Reversible 
terminator 
chemistry 
2*125bp Solid phase 
Human WGS, 
WES, RNA-seq 
and methylation 
ABI/Life 
Tech SOLiD 
Sequencing by 
ligation 2*60bp 
Emulsion 
PCR 
Human WGS, 
WES, RNA-seq 
and methylation 
Polonator 
Reversible 
terminator 
chemistry 
25-55bp Single molecule 
Human WGS, 
WES, RNA-seq 
and methylation 
* WGS represents Whole Genome Sequencing; WES represents whole exome sequencing 
1.1.2 DNA NGS data analysis workflow     
      In the practice of DNA NGS data analysis (Figure 1.1), for each analyzed 
sample, fastq files with sequencing reads are provided. The first step usually 
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involves prior sequencing data quality control using software such as FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to perform sequence 
trimming and make sure the overall sequencing data quality is sufficient to perform 
downstream analysis. After that, the reads can be aligned to a human genome 
reference [4] using alignment tools such as BWA [5] and novoAlign 
(http://www.novocraft.com/products/novoalign/), followed by local reads realignment 
using GATK [6] and PCR duplicate removal using Picard 
(http://sourceforge.net/projects/picard/) or Samtools [7]. After obtaining a bam file of 
aligned and filtered reads, further data quality assessments should be performed to 
evaluate the read duplicate rate, coverage, and coverage uniformity. This step is 
very useful in evaluating the workability of a sequencing platform and the quality of 
sequenced samples.  
        After data quality assessment, multiple types of genomic alterations such as 
single nucleotide variant (SNV), small insertions and deletions (indels), structural 
variants (SV) and copy number alterations (CNA) could be investigated. There have 
been multiple algorithms developed for each type of genomic alteration study, for 
example, VarScan2 [8], GATK [6] and Mutect [9] are the most popular SNV 
detection tools and achieve high accuracy; GATK [6], Pindel [10] and Scalpel [11] 
are well known in detecting indels; BreakDancer [12], DELLY [13] and novoBreak 
are capable of detecting SVs; ExomeCNV [14], EXCAVATOR [15], and CONTRA 
[16] are well known algorithms for detecting CNAs. One challenge of using these 
tools is that none of them generally performs best for all sequencing platforms or 
types of sequencing data, therefore, given the specific data type, a detailed 
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comparison should be performed to make sure the tool achieves a good 
performance on the given data. 
 
Figure 1.1 A pipeline overview of DNA next generation sequencing data analysis 
 
        After detection of genomic alterations, one critical step is to annotate the 
mutations from the genomic level to the protein level. There have been many tools 
developed to perform such mutation annotation, such as ANNOVAR [17], Variant 
effect predictor (VEP) [18], SnpEff [19] and Oncotator [20]. Each tool was 
implemented with different annotation roles as defined by the developers and 
preferentially uses different transcript databases among Ensembl [21], Refseq [22], 
UCSC [23], GENCODE [24], etc. Another important step is to characterize functional 
mutation events that could potentially drive disease development or represent 
indications of clinical diagnostics and drug treatment. In this step, several driver 
mutation prediction algorithms were widely used such as CanDrA [25], CHASM [26], 
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VEST [26], TransFIC (http://bg.upf.edu/transfic/home) and MutationAssessor [27] to 
predict a genomic SNV is a driver mutation or not. In addition, some databases such 
as myCancerGenome in Vanderbilt University (http://www.mycancergenome.org) 
and the Institute for Personalized Cancer Therapy in MD Anderson Cancer Center 
(http://pct.mdanderson.org) have actively curated the potentially clinically functional 
and actionable mutations through literature learning and collected protein variants 
that could potentially be used to indicate clinical therapy responses. 
1.1.3 Challenges of DNA clinical sequencing and analysis         
        With the development of sequencing technologies over the last decade, there 
are many different types of sequencing which have become routinely used in 
scientific research, such as whole genome sequencing (WGS), exome sequencing 
(WES), RNA sequencing and methylation sequencing. In addition, as it comes to 
measure the applicability of using sequencing data to enhance health management 
and clinical treatment, many more cost-effective and practical methods have been 
developed and applied, such as target of DNA sequencing, which significantly 
enhances the affordability of utilizing sequencing data in clinical management.  
        There are already a lot of exciting applications of using whole-genome 
sequencing and exome sequencing to improve the understanding of inheriting 
familiar diseases. For instance, a direct relationship between a specific gene locus 
and disease was revealed by studying a family with four siblings that were affected 
by Charcot-Marie-Tooth disease (a peripheral polyneuropathy) [28]. Furthermore, 
analyses focusing on individual genomes have also been published previously [29-
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32], including the first complete individual high-throughput method [33]. 
         Besides the familiar inherited diseases, cancer is a class of diseases that 
consist of multiple disease types and could potentially benefit from the application of 
personalized therapeutic approaches, particularly given the wide spectrum of 
mutations that must be analyzed and the complexity of cancer-related genome 
variation: germline susceptibility, somatic single/multiple nucleotide substitutions and 
small insertion/deletion mutations, copy number variations, and structural variants.  
         Although it was increasingly recognized that the personal genome profiles 
obtained from clinical sequencing data can help inform more accurate clinical 
decision making [33, 34], the implementation of cancer genomic medicine is critically 
constrained by a lack of precise understanding of the impact of individual somatic 
mutations on tumor pathophysiology and response to cancer therapy. Currently, 
multiple challenges still exist to accomplish the goal of personalized therapy. For 
example, 1) limitations of current sequencing technologies and computational 
algorithms in accurately characterizing genomic alterations such as sequencing 
error, inadequate coverage and uneven coverage uniformity, which may cause loss 
of information that can be used in clinics; 2) Inconsistent annotations among 
different data sources and tools, which lead to an ambiguous interpretation of 
mutation consequences in clinical diagnostics and biomarker indications; 3) The lack 
of ability to distinguish genomic alterations that confer tumorigenesis (i.e. drivers), 
from those that provide no selective advantage to tumor growth but occur 
stochastically in cancer development; 4) Inadequate practice of using -omics data to 
reveal the specific function of different genomic alterations in different diseases and 
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biological contexts.  
1.2 Mutation annotation in NGS data analysis 
        Downstream interpretation of genomic alterations that are characterized in 
mutation detection algorithms is a critical component in NGS data analysis, bridging 
the identification of mutations and the application in determining functional and 
disease relevant mutations. One fundamental utility of variant annotation is to 
categorize each variant based on its relationship to coding sequences in the defined 
genome and see how it may change the coding sequence and then affect the protein 
level structure.  
        The coding sequences of the reference genome refer to, generally speaking, 
the genes. The “gene” comes to refer to a genomic region that produces poly-
adenylated mRNAs through transcription and followed-up translation that encodes 
an expressed protein [7]. To date, our principal understanding of the protein-coding 
sequences in the human genome is summarized in the set of transcript isoforms we 
continuously curate and believe to exist. Thus, in the mutation annotation, the 
annotation depends on the set of transcripts that were given. There are several 
widely used annotation databases and browsers such as Ensembl [21], Refseq [22], 
GENCODE [24], and UCSC [23], which independently contain different sets of 
transcripts that can be used for variant annotation, as well as a wealth of information 
of many other kinds as well, such as ENCODE [35] data about the function of non-
coding regions of the genome. In this way, a transcript set may also include 
information about non-coding regions in the genome that mainly function by 
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regulating the expression of coding transcripts. 
         Variant annotation could be straightforward and unbiased, in the cases that, 
only one transcript exists for the gene in which the given genomic variant locates or 
different transcripts exist for the gene but the given genomic variant locates in a 
position where identical coding sequences are obtained based on different alterative 
splicing. However, frequently we encounter more complex situations in the 
annotations. One situation is that a genomic variant could be transcribed by different 
transcripts and then further translated into proteins with the variant in different 
relative positions, then the question is about which one transcript to choose to report 
as the annotation result for the given variant. Another situation is a genomic variant 
is annotated by different transcript databases and then further translated into 
proteins with the variant in different relative positions, then the question will be which 
database to use for the annotation. When a genomic variant is mapped to multiple 
potential genes, the situation can be even more complex as prioritizing the genes 
should be performed in addition to choosing a transcript.  
        Based on the above mentioned facts, different transcripts existing for one 
particular gene and even different genes share a similar sequence in the DNA level, 
therefore the usages of different transcript isoforms or annotation tools would likely 
produce discordant protein variants given an identical genomic variant. 
1.3 Mutation annotation ambiguities in translational and functional genomics 
study 
1.3.1 Forward annotation        
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        In a functional genomics study, the biologists frequently want to validate a set 
of putative functional mutations with the help of bioinformatics analysis. Frequently, 
people would prefer to nominate the functional mutation candidates based on the 
variant frequency. This scenario requires a precise estimation of the variant 
frequency in a mutation cohort or across different mutation cohorts. However, 
different annotation practices, especially for data from different cohorts, would 
produce inconsistent annotation results for a genomic variant based on different 
transcript usages, and therefore underestimate the variant frequency and lose 
potentially promising candidates for functionally relevant study. For example, 
chr7:g.55221821G>A was annotated to EGFR:A244T based on transcript 
ENST00000455089, while was annotated to EGFR:A289T in COSMIC based on 
transcript ENST00000275493. EGFR:A244T was considered as a hotspot mutation 
in TCGA; However, EGFR:A244T does not even exist in COSMIC because the 
identical genomic variant was annotated to a totally different protein variant 
EGFR:A289T, which may be confusing when researchers look at these two 
annotation results separately and would argue that whether EGFR:A244T is a truly 
functional mutation since it was observed in TCGA but not in COSMIC. 
        Lack of specification can clearly affect the interpretation of variants and may 
have serious implications for patient management as well as for understanding of 
the biology. For example, it has been shown that cancer cells that carry 
BRAF:V600E have higher sensitivity to RAF inhibitors (RAF265 and PLX4720) than 
those with other BRAF:V600X variants [36]. If only the amino acid position and the 
reference amino acid are given (e.g. BRAF:V600), a treatment with little likelihood of 
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benefit for the patient might be selected [37]. Inconsistent annotations can result in 
discordance among molecular testing results from different laboratories, generating 
difficulties for clinical decision-making, particularly in the absence of strong decision 
support. For example, ABL:T315I and ABL:M351T, which are frequently seen in 
chronic myeloid leukemia patients, confer resistance to Imatinib treatment [38], but 
they can also be reported as T334I and M370T, respectively, based on different 
transcript isoforms. That difference in annotation may mislead the clinical decision-
making.  
        In genetic diagnosis or counseling for germline variants, the mutation 
annotation ambiguities could also be misleading. For example, 
chr10:123258036A>C, which is associated with Crouzon Syndrome [39], can be 
annotated as N550H in FGFR2b or N549H in FGFR2c. However, it could also be 
annotated as N432H, N433H, N460H and N461H based on the usage of other 
transcript isoforms. Those variants have not been shown to be associated with 
Crouzon Syndrome in any literature or clinical reports. If a variant annotator chooses 
to report one of the variants not known to be associated with Crouzon Syndrome, a 
clinical diagnosis or counseling opportunity might be missed. 
1.3.2 Reverse annotation        
        Conversely, different DNA variants such as chr7:55249076_55249077CT>AG 
and chr7:55242470T>C can result in the same cDNA and protein variant, 
EGFR:p.L747S, which mediates acquired resistance of non-small cell lung cancer to 
tyrosine kinase inhibitors [40]. However, the multiple options of genomic variants for 
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the protein variant could lead to another commonly encountered issue, which is 
uncertain genomic origin for a given protein variant. This exposes an important gap 
in the clinical genomic validation process, for example, when a biological researcher 
or a clinician observes EGFR:p.L747S in a genetic report as mentioned above, 
without the information of concrete transcript ID and genomic origin, it is impossible 
to precisely determine how to construct the cDNA sequence for experimental 
functional validation. 
1.3.3 Limitations of current variant annotation algorithms         
         Differences among widely used annotation algorithms such as ANNOVAR [17], 
SnpEff [19] and VEP [18] and among various transcript databases such as Ensembl 
[41], RefSeq [42] and GENCODE [24], further increase the extent of ambiguity. Ad 
hoc post-annotation filters such as reporting of the variant on the longest transcript 
may also be a problem because the longest transcript may be different in different 
systems and, further, may not represent the transcript actually present. Inconsistent 
use of conventions in annotating indels, i.e., reporting the left-most (left-aligned) or 
the right-most (right-aligned) position in the context of repetitive sequences can 
further increase ambiguity. A recent investigation indicated that variable usage of 
annotation algorithms and/or transcript databases may cause greater than 50% 
discrepancy in annotating loss-of-function variants identified from genomic 
sequencing [43]. Our investigation of the COSMIC database reveals that 92,444 out 
of 1,010,316 (9.1%) of somatic DNA variants have been reported more than once at 
different locations on proteins based on differences in isoform. 
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        Despite such significant challenges in ongoing research and clinical practice, 
we have not had an annotation tool that is capable of quantifying the extent of such 
ambiguities and resolving them in a systematic way. Existing tools (e.g., ANNOVAR, 
snpEff and VEP) perform what we call “forward annotation”, which maps a variant 
characterized at the genomic level to a set of cDNA or protein isoforms. No tool, to 
the best of our knowledge, has general capability for what we call “reverse 
annotation,” which reverse-maps a variant at a cDNA or protein level to the genome. 
A previous algorithm, Mutalyzer [44], can reverse-annotate variants at the cDNA 
level, but it has limited functionality: it annotates only single nucleotide variants; it 
does not allow input of a gene name, nor offering analysis of variants at the protein 
level. Without a fully automated reverse annotation tool, translation from a functional 
protein site (such as Y308/S473 in AKT and Y1068/Y1172 in EGFR) to a genomic 
identifier would involve a tedious manual process that is not scalable.  
1.4 Cancer gene prediction 
        With the increasingly used NGS data in biomedical research, a hot topic has 
been cancer gene identifications. The main goal was to find gene candidates that 
could drive the cancer development, promote cancer cell proliferation or enhance 
the cancer cell viability. To achieve this goal, there have been several methods that 
were developed in the past few years to predict driver genes. Essentially, different 
methods have largely diverse assumptions for defining driver genes and differences 
in the results reflect the differences in the methodologies.  
        One assumption was to consider all significantly mutated genes across the 
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cancer genome as driver genes. Motivated by that, a gene is nominated as a driver if 
it contains significantly more mutations than expected from a null background model 
[45, 46]. A variety of practical algorithms have been developed in the context of 
large-scale cancer genome sequencing, differing mainly in how they model 
background mutations. For example, MuSiC [47] assumes a homogenous 
background mutation rate across all genes. In each individual gene, a binomial 
model is used to calculate the significance level (p value) of each mutation subtype, 
then Fisher’s method is applied to combine the p values across different mutation 
subtypes and come up with an unified p value to indicate the significance level of the 
investigated gene. With realizations that the background mutation rates were not 
uniform across all the genes, MutSigCV [48] models the heterogeneous background 
mutation rate for each gene–patient–category combination based on the observed 
silent mutations in the specifically investigated gene and non-coding mutations in the 
surrounding chromosomal regions. Because in most cases these data are too 
sparse to estimate an accurate background mutation rate, the method tries to 
increase the accuracy by pooling data from other genes with similar properties (for 
example, replication time, expression level). Furthermore, the method identifies the 
significantly mutated genes by incorporating factors such as di-nucleotide sequence 
context, cancer type and epigenetic elements.  
        The other assumption was that driver genes tend to have highly recurrent 
mutations that are enriched in clusters. Some algorithms have also been developed 
to nominate driver genes using cluster-based methods. For example, 
OncodriveCLUST [49] estimates a background model from coding-silent mutations 
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and tests whether the mutations on each individual site are significantly mutated, 
after that, the method arbitrarily chooses to combine mutational hotspots that are 
within 5 amino acids of each other, and detects clusters of missense mutations that 
are significantly mutated and therefore where driver genes lie. Essentially, those 
clusters would be likely to contain mutations that can alter the protein structure and 
thus affect the gene function during cancer development. E-Driver [50] exploits the 
internal distribution of missense mutations between different proteins’ functional 
regions (for example, functional domains or intrinsically disordered regions) to 
nominate clusters of missense mutations in protein-protein interaction (PPI) 
interfaces that show a bias in their mutation rate as compared with other regions of 
the same protein, providing evidence of positive selection and suggesting that these 
proteins may be actual cancer drivers.  
        However, increasingly many studies indicate that a mutation may have 
substantially different functions at different amino acid positions in the same gene 
[51, 52] and may be associated with different clinical utilities in different disease and 
biological contexts [53, 54]. Similarly, not every mutation within a cancer gene can 
be assumed to have equal function in one cancer type or across different cancer 
types. In addition, the previous studies that focused on identifying significantly 
mutated genes mostly ignored potential functional mutations in infrequently mutated 
genes, and in under-investigated mutation types such as insertions and deletions.  
1.5 Driver mutation prediction 
        To characterize the function of individual mutations, multiple computational 
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tools such as TransFIC (http://bg.upf.edu/transfic/home) [55], CHASM [26], Condel 
[56], MutationAssessor [27] and CanDrA [25] have been developed. Essentially, 
CHASM uses a random forest classifier and incorporates 49 features to rank the 
investigated mutations with different probabilities of being driver (the lower p-value 
indicates higher driver potential). In terms of the training data, CHASM uses 
manually curated oncogenic functional mutations as true drivers from breast, 
colorectal, and pancreatic tumor resequencing studies [46, 57] and the COSMIC 
database [58], and uses synthetic passenger mutations that are generated by 
sampling from eight multinomial distributions that depend on dinucleotide context 
and tumor type [26]. CanDrA uses a support vector machine classifier and 
incorporates 95 different features to classify the investigated mutations to be either 
driver or passenger in a tumor type-specific manner. In terms of the training data, 
CanDrA defines a driver mutation as one that is observed in at least two different 
samples, from either TCGA or COSMIC. Compared to CHASM and CanDrA, other 
methods such as Condel, MutatationAssessor, Polyphen2 [59] and SIFT [60], tend 
to use a scoring system to predict the functional impact of a mutation. For example, 
Condel uses a weighted average of the normalized scores that are integrated from 
five different tools including Logre, MAPP, MutationAssessor, Polyphen2 and SIFT. 
TransFIC takes as input the Functional Impact Score of a somatic mutation 
observed in cancer provided by MutationAssessor, Polyphen2 and SIFT. It then 
compares that score to the distribution of scores of germline SNVs observed in 
genes with similar functional annotations (for instance genes with the same 
molecular function as provided by the Gene Ontologies), and eventually reports a Z-
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score to indicate the tolerance of the mutation. 
        Although the algorithms have been actively used in identifying functional 
mutations from multiple aspects and contributed significantly to the cancer research, 
several limitations have been frequently observed: 1) Many algorithms are designed 
to tackle a generic problem about the function of a driver, but do not account for 
cancer type specificity and ignore the potential functional heterogeneity of a mutation 
in different cancers; 2) Many machine leaning-based algorithms simply select as 
positive training data mutations in known cancer genes, which may significantly bias 
the assessment of mutations in previously unknown non-cancer genes, while it is 
unfair to assume that the driver mutations only occur in known cancer genes; 3) 
Previous studies generally lack adequate functional assessment, which usually 
involves interrogation of RNA expression, protein activity and drug response data, to 
investigate the biological and therapeutic relevance of predicted mutations; 4) All the 
algorithms predict a large number of driver mutations (most are non-recurrent) and 
thus significantly sacrifice specificity, which is impractical for thorough functional 
genomic validations and individual evaluations using currently available functional 
data.  
        Since the potential driver mutations are supposed to be defined under a 
specific disease context, a driver mutation prediction algorithm that does not take 
into consideration disease-specific factors such as cancer type, disease stage, 
mutation prevalence, mutation spectrum, and other clinical characteristics, may not 
be accurate enough. As a result, these functional predictions often disagree with 
each other and are not accurate enough for practical use. The number of clinically 
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actionable mutations, which could potentially be used as training data, will likely 
remain in the hundreds (currently 285 in MyCancerGenome.org and 269 in 
PersonalizedCancerTherapy.org). Therefore, it is critical to improve predictive 
approaches that do not completely rely on known actionable mutations, but are 
capable of accurately predicting driver mutations. 
1.6 Application of high-dimensional -omics data in translational genomics 
        With the accumulating knowledge of cancer genome, many genetic variants 
have been shown to affect tumor expression architecture through the transcriptional 
regulation either in -cis or in -trans manner [61, 62]. The effort to map genetic 
variation to specific expression quantitative trait loci (eQTL) has illustrated the value 
of transcriptomics data in the functional interpretation of genetic variants [63]. Thus, 
the transcriptomics data could serve as a unique resource to evaluate the impact of 
individual genomic mutations on the expression level. In addition to transcriptomics 
data such as RNA sequencing or microarray data, in the past few years, proteomics 
data such as Mass Spectrometry [64] or Reverse Phase Protein Array (RPPA) [65] 
has become one of most promising data types for investigating biological activity at 
the gene/pathway level, as well as the effects of post-translational modification. 
Therefore, in terms of investigating the genome-wide effect of genomic alterations, 
proteomics data will serve as a novel data type. 
        Cancer pharmacogenomics studies have recently become an important way for 
discovering the molecular determinants of drug response, thus representing the 
potential benefits of personalized cancer treatment. Multiple works such as seminal 
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work on the NCI-60 cancer cell lines [66, 67] and other subsequent research efforts 
[68, 69] highlighted specific genetic alterations as drug targets or biomarkers of drug 
response. For example, BRAF:V600E and NRAS mutations have been shown to 
increase cancer cell sensitivity to MEK inhibitors (such as AZD6244) [53, 70]. 
However, it was also elucidated that cells with BRAF:V600E mutations are sensitive 
to RAF inhibitors in melanoma but not in colon cancer [70], which suggested the 
disease specificity of the biomarker indication. The emerging large-scale 
pharmacogenomics datasets such as CCLE [71] and GDSC [72] have been 
designed to facilitate an increased understanding of the molecular features that 
influence drug response in cancer cells and will enable the design of improved 
cancer therapies. 
1.7 Impact of variant annotation on hotspot mutation prediction 
        Regarding hotspot mutations, it is common to make predictions using either 
genomic or protein variants. Many computational algorithms have tried to predict the 
impact of functional mutations on the genomic level [25, 26, 60]. Compared to using 
genomic variants, one advantage of using protein variants is to substantially 
increase the statistical power, since different genomic variants could happen at one 
identical protein amino acid position and actually represent very similar biological 
functions [73, 74]. For hotspot mutation prediction that relies on the amino acid 
residue information, it is important to have a correct representation of the protein 
variant frequency within a defined cohort or across different cohorts. Fundamentally, 
the protein variant was inferred from the genomic variant that was detected in each 
sample within a specific cohort, therefore, it is important to know that whether an 
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observed protein variant was from one single genomic variant and whether a 
genomic variant was annotated to a uniform protein variant. 
       The variant annotation process from the genomic to protein level, is not an 
absolute one-to-one correspondence. Ambiguities may come from: 1) different 
annotation rules that are implemented; 2) different transcript databases that are 
used; 3) different transcript isoforms that are used within one identical transcript 
database. Due to those concerns, one genomic variant is frequently annotated to 
various protein variants in different practices. This means if we solely use the protein 
residue information to identify the functional variants such as hotspot mutations, the 
frequency of protein residues could be largely underestimated and the function of a 
specific protein residue may be misinterpreted because of incorrect frequency 
calculations.  
1.8 Motivations and Rationale of the thesis study 
        Next generation sequencing has been recognized as an effective approach to 
enhance the accuracy and efficiency of cancer patient management. Based on the 
massive information that is obtained from analyzing such high dimensional data, we 
could potentially achieve the goals of personalized therapy. Through the 
investigations since the emergence of NGS techniques, the accuracy of applying the 
NGS data in clinics has been largely constrained by many different aspects, such as 
clinical detection, annotation and interpretation of the variants that were observed in 
clinical sequencing data.  
        A large amount of ambiguity exists in current mutation annotations, which could 
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potentially prevent the precise identification of functional mutations, biomarkers, and 
target therapies in basic research and clinical practice. For example, one genomic 
variant can be annotated to different protein variants based on different transcript 
isoform usages within one dataset or across different datasets, which could lead to 
significant underestimation of targeted protein variant frequency and 
misinterpretation of the functional impact of the targeted protein variant. Due to the 
annotation ambiguities, the genomic variant that corresponds to a protein biomarker 
for a drug treatment indication could be annotated to another different protein variant 
and lead to incorrect clinical decision-making. Given these problematic practices in 
research and in clinics, it is important to systematically investigate the existence of 
annotation ambiguities in the commonly used mutation datasets such as COSMIC 
and TCGA. In addition, development of a method that enables cross-level variant 
annotations, would allow the researchers and clinicians to fully capture the potential 
genomic origins of an observed protein variant and minimize the ambiguities of using 
genomic information to make a decision. Motivated by these considerations, we 
developed a novel variant annotator, TransVar, which performs multi-level variant 
annotation such as forward annotation from genomic to RNA and to protein level, 
and reverse annotation from protein to RNA and to genomic level. The novel reverse 
and equivalence annotation function of TransVar could potentially contribute in: 1) 
experimental validation design; 2) clinical pharmacogenomics; and 3) hotspot 
mutation prediction. 
        Another critical challenge of oncogenomics and pharmacogenomics is to 
distinguish genomic alterations that confer tumorigenesis (i.e. drivers), from those 
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that provide no selective advantage to tumor growth but occur stochastically in 
cancer development. Previously many driver gene algorithms have been proposed 
to distinguish cancer related genes that could promote cancer development. 
However, more recently researches found that 1) it is incorrect to assume equal 
function of different mutations within one cancer gene in all cancer types. For 
example, one mutation such as BRAF:V600E, can have different functional 
indications in different cancer types. In BRAF, quite a lot of mutations do not actually 
have clear functional indications in many cancer types; 2) it is unfair to simply focus 
on significantly mutated genes while ignoring infrequently mutated genes. More and 
more studies indicate now that infrequently mutated genes could also be functional 
in certain cancer types. After that, some driver mutation algorithms were proposed to 
distinguish driver mutations from passengers. However, most of the methods still 
assume the same function of a variant in different cancer types; they did not 
consider using additional functional data to justify the performance of the driver 
mutation prediction, and they do not assess the function of a variant in a specific 
biological context. Therefore, people gradually realized that it is important to obtain 
accurate biological and therapeutic interpretations of a mutation in a tumor type-
specific manner to help improve the efficacy of using genomics information in clinical 
applications. With those motivations, we systematically identified tumor type-specific 
hotspot mutations in 17 tumor types, and analyzed the potential impact of hotspot 
mutations by performing genome-wide and population-based analysis across 
different tumor types and assessing functionality using transcriptomics, proteomics 
and pharmacogenomics data.  
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CHAPTER 2 
 
TransVar: a multi-level variant annotator for precision genomics 
 
 
(Most of the methods and results in this chapter have been published online in 
Nature Methods, November 2015: Wanding Zhou, Tenghui Chen, Zechen 
Chong, Mary A Rohrdanz, James M Melott, Chris Wakefield, Jia Zeng, John N 
Weinstein, Funda Meric-Bernstam, Gordon B Mills, and Ken Chen, “TransVar: 
a multilevel variant annotator for precision genomics”. According to the 
journal policy, the author retains the right to include the published article in 
full or in part in a dissertation.) 
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2.1 Materials and Methods 
2.1.1 COSMIC and TCGA somatic mutation data 
        We downloaded the COSMIC somatic mutation dataset version 67 for our 
study. As introduced in the COSMIC data source, this total mutation set includes 
many sources of curated mutation data. In terms of TCGA mutations, we 
downloaded TCGA pan-cancer level-3 somatic mutation data from Synapse 
(https://www.synapse.org/#!Synapse:syn300013) as last updated in November 
2014. 
2.1.2 Transcriptome definitions 
        For human genome reference, TransVar supports hg18, hg19 and hg38. 
TransVar supports transcriptome definitions in 1) UCSC knownGene [75], 2) 
RefGene built from the UCSC table browser [76], 3) Ensembl annotation [41] in 
General Transfer Format (GTF), 4) RefSeq annotation [42] in General Feature 
Format version 3 (GFF3), 5) Consensus Coding Sequence (CCDS) [77], 6) 
GENCODE [24] release 19, and 7) AceView [78]. TransVar not only supports the 
transcript annotation in human, but also supports which in mouse. When using 
TransVar, the users can use any one or a combination of different transcript sources 
or else user-provided definitions (such as ncRNA and miRNA databases, as long as 
they are based on the same genome reference assembly).  
2.1.3 Reverse annotation 
         TransVar is designed for reverse annotation of four categories of mutations at 
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the mRNA level (single-nucleotide substitution, insertion, deletion and block 
substitution) and four categories of aberrations at the protein level (single-amino acid 
substitution, insertion, deletion and frame-shift). The input format of TransVar was 
designed to follow the Human Genome Variation Society (HGVS) nomenclature 
(http://www.hgvs.org/mutnomen/) [44]. Small formatting variation from HGVS is 
allowed to accommodate non-standard identifiers frequently seen in the literature (as 
illustrated by examples on the web site, www.transvar.net). The output of TransVar 
strictly follows the HGVS nomenclature. For each input variant, based on the gene 
name and the correspondingly available transcript information in the defined 
databases, TransVar iterates through all of the associated transcripts and infers the 
relative coordinates on each transcript based on the genomic coordinates of the 
coding sequence defined for each transcript. TransVar builds in multiple checkpoints 
to restrict the search scope of valid transcripts. That filter takes into account: 1) the 
length of the transcript, 2) the sequence of the optionally provided reference 
transcript or isoform, 3) exon boundaries in the transcript, and 4) any transcript 
identifiers provided. For protein-level variants, TransVar provides parsimonious 
inference of nucleotide changes that could best explain the observed amino acid 
change. Taking single-amino acid substitution as an example, TransVar iterates over 
all possible target codon sequences to identify a set of most likely base changes that 
minimize the distance between the altered codon and the reference sequence in 
each transcript. Meanwhile, TransVar outputs all candidate variant identifiers to a 
report that informs the user of all possible sourcing variant annotations.  
        For insertions and deletions, TransVar aligns the alternative indel sequences to 
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the reference sequence when generating identifiers at the mRNA and protein levels, 
conforming to the HGVS nomenclature. TransVar uses a walk-and-roll strategy for 
the realignment to ensure accurate positioning of the resulting identifiers despite the 
presence of repeats, intron splicing, and redundant codon usage. Contrary to the 
HGVS specification---3ʹ-alignment (or right-alignment or C-terminal-alignment under 
the protein representation) of indels---a commonly used rule in the genomics 
community is to 5ʹ-align (or left-align or N-terminal-align) indels. Thus, TransVar also 
provides a left-aligned identifier in the output to allow users to reference annotations 
created under other rules. For frame-shift variants, TransVar iterates from the 
reported location all possible single and double nucleotide insertions and deletions 
and reports those that result in the corresponding frame-shift at the protein level, as 
delimited by the amino acid sequence between the first altered amino acid and the 
first stop-codon. 
2.1.4 Forward annotation 
        Forward annotation starts from a genomic location. The input follows HGVS 
nomenclature (http://www.hgvs.org/mutnomen/) [44] and small formatting variations 
are allowed (as illustrated in the examples on the web site). The output strictly 
follows HGVS nomenclature. TransVar hashes transcript definitions based on each 
transcript’s start and end positions and retrieves all of the isoform definitions that 
overlap with the genomic coordinate of the input identifier. If the input variant falls 
within the span of an exon, TransVar reports the consequence of the variant and 
generates variant identifiers at both the mRNA and protein levels. TransVar also 
reports mRNA identifiers for variants that overlap intronic or UTR regions. Additional 
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sequence features can optionally be hashed to allow more extended annotation of 
regulatory elements. Those features are similar in concept to ones in existing 
annotators such as ANNOVAR, snpEff and VEP. 
        The input to TransVar can use a specific variant (e.g., 
chr6:g.4241214_4241218del) or simply a genomic interval (e.g., 
chr6:g.4241214_4241218) without specifying the reference and alternative alleles. 
For example, chr6:g.4241214A>T denotes a single-nucleotide substitution, whereas 
omitting the alternative allele T indicates a single genomic position. Both forms are 
valid inputs to TransVar. The annotation of genomic position/interval is of great utility 
for understanding the potential translational consequences of indels and structural 
variations (SVs) if the corresponding breakpoints on the transcripts can be revealed. 
For example, for chr3:g.178936091_178936192, a 102-bp interval, one can use 
TransVar to show that it encodes PIK3CA:p.E545_R555, which begins in the coding 
sequence of PIK3CA exon 10 and ends in the intron between exon 10 and 11, 
covering codons 1633 to 1664 and 70 intron bases. That variation may introduce not 
just an indel but also a novel splicing, resulting in complex mRNA and protein 
products. Given a long altered genomic interval, TransVar can also reveal which 
genes are contained within the interval. 
2.1.5 Equivalence annotation 
        TransVar automates the search for alternative codon identifiers that are 
potentially of the same genomic origin, a task we call “equivalence annotation.” Two 
codon identifiers such as MET:p.T1010 and MET:p.T992 are considered equivalent 
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because they can be translated from the same genomic variant 
chr7:g.116411990C>T, based on different isoform definitions. The equivalence 
annotation functionality can be used to ascertain the functional or clinical 
interpretation of important variants and also provide more accurate estimation of 
variant frequency in a disease cohort. For a protein level identifier, TransVar 
performs reverse annotation and then forward annotation to map the resulting 
genomic variants back to protein level. Both steps may result in multiple valid 
candidate identifiers that are equivalent to the original variant. All of the equivalent 
identifiers are reported in the TransVar output. By providing specific transcript 
identifiers from different databases, TransVar allows the user to map a protein-level 
variant annotated using one of the databases (e.g., RefSeq) to protein-level variants 
annotated using a different database (e.g., Ensembl). That type of analysis can be 
particularly important for decision support in patient management. For example, 
MET:p.T1010 is generally designated as an activating germline SNP, whereas 
MET:p.T992 is not annotated in most decision-support algorithms [79]. 
        TransVar maximally uses available information such as reference sequence to 
reduce the number of equivalent identifiers. For example, for ABL1:p.255, TransVar 
finds 6 equivalent codon identifiers (p.236, p.237, p.254, p.256, p.273, and p.274) in 
the RefGene database. When the reference amino acid (E) is provided, only 2 
codons remain (E236 and E274), instead of 6. Including the reference amino acid 
can substantially reduce the number of equivalent identifiers. For example, for a set 
of 1821 hotspot mutations in COSMIC, specifying the reference amino acid reduces 
the number of mutations with non-unique codon identifiers from 1260 (69.19%) to 
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1021 (56.07%) based on Ensembl v75. 
2.1.6 Tool Implementation 
        TransVar provides reverse, forward and equivalence annotation algorithms that 
can be accessed via a command line utility, a programmable Python API, or a web 
interface (www.transvar.net). The web interface uses application programming 
interface (API) calls in the common gateway interface (CGI) and allows use of 
TransVar without writing code or issuing commands in a terminal. The user can 
either type in the variant identifiers or upload a file for batch processing. TransVar 
can optionally load the coordinates of the entire transcriptome definition into memory 
but reads in the corresponding reference transcript/protein sequences only when 
necessary. That procedure limits the memory footprint to the size of the 
transcriptome definition. For the web interface, the transcript definitions are stored in 
disk-indexed database tables. Gene names (in the case of reverse annotation) and 
genomic locations (in the case of forward annotation) are indexed to facilitate quick 
look-up. TransVar can map directly to different versions of human genome 
assemblies. Choices of reference assemblies and transcript definitions are provided 
as options in the web-form submission. Each line characterizes the annotation 
based on one specified transcript definition. If no valid gene name matches or if no 
transcript definition matches, a warning message is provided in the last field of the 
output. 
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2.2 Results 
2.2.1 Overview of the functions of TransVar 
        To facilitate standardization and reveal inconsistency in existing variant 
annotations, we have designed a novel variant annotator, TransVar, to perform three 
main functions supporting diverse reference genomes and transcript databases 
(Figure 2.1): (i) “forward annotation”, which annotates all potential effects of a 
genomic variant on mRNAs and proteins; (ii) “reverse annotation”, which traces an 
mRNA or protein variant to all potential genomic origins; and (iii) “equivalence 
annotation”, which, for a given protein variant, searches for alternative protein 
variants that have identical genomic origin but are represented based on different 
isoforms.  
         Essentially, uncertainty frequently exists in mutation annotation. One DNA 
sequence with a mutation could be transcribed into different transcript isoforms 
based on alternative splicing, and therefore be further translated into proteins with 
the mutation on different relative positions (Figure 2.1 Upper). For example, 
chr14:g.105239423C>T (hg19) can be forwardly annotated to coding mutations 
AKT1: E17K, AKT1: E322K or non-coding mutation AKT1:intronic. Compared to 
forward annotation, reverse annotation from the protein level to genomic level is a 
novel concept. One protein with a variant could potentially come from multiple 
transcripts with the mutations on various locations, and multiple genomic variants 
are responsible for each of the corresponding transcript (Figure 2.1 Lower). For 
example, EGFR: p. L747S (hg19) can be reversely annotated to  
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Figure 2.1 Overview of TransVar. TransVar performs forward (green arrows) and reverse 
annotation (pink arrows) and considers all possible mRNA transcripts or protein isoforms 
available in user-specified reference genome and transcript databases (colored boxes 
representing exons in various transcripts or isoforms of a gene). Given a variant (black 
triangle) at any of the genomic, mRNA or protein levels, TransVar is able to infer the 
associated variants at the other two levels. In reverse annotation, TransVar searches all 
potential transcripts and reports one variant on each transcript. When there are multiple 
variants on the same transcript, TransVar reports the variant with minimal nucleotide 
changes (red text) instead of other alternatives (purple text). (Figure reprinted from 
TransVar: a multilevel variant annotator for precision genomics. Wanding Zhou, Tenghui 
Chen, Zechen Chong, Mary A Rohrdanz, James M Melott, Chris Wakefield, Jia Zeng, John 
N Weinstein, Funda Meric-Bernstam, Gordon B Mills, and Ken Chen, Nature Methods, 
2015. According to the journal policy, the author retains the right to include the published 
article in full or in part in a dissertation.) 
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chr7:g.55242470T>C and chr7:g.55249076_55249077delinsAG. In addition, multiple 
genomic alterations on an identical transcript may result in a similar protein variant. 
        In the reverse annotation practice of TransVar, When there are multiple 
variants on the same transcript, TransVar reports the variant with minimal nucleotide 
changes chr7:g.55242470T>C and chr7:g.55249076_55249077delinsAG, instead of 
other alternatives such as chr7:g.55242470_55242471delinsCT, and 
chr7:g.55249076_55249078delinsTCG. 
2.2.2 Forward annotation of COSMIC mutations using TransVar, ANNOVAR, 
VEP, snpEff and Oncotator 
         To illustrate the degree of inconsistency in existing variant data and evaluate 
TransVar’s accuracy in performing comprehensive annotation, we conducted 
forward annotation on COSMIC mutation data v67, using TransVar and several 
widely used variant annotators, ANNOVAR [17], VEP [18], snpEff [19], and 
Oncotator [80], and asked whether the resulting protein identifiers (gene name, 
protein coordinates, and reference amino acid (AA)) match those in COSMIC.  
         We downloaded 964,132 unique single-nucleotide substitutions (SNSs) such 
as chr1:g.87369101C>A, 3,715 multi-nucleotide substitutions (MNSs) such as 
chr10:g.52595929_52595930delinsAA, 11,761 in-frame and frame-shift insertions 
such as chr2:g. 69741762_69741762insTGC and chr12:g. 9021138_9021138insG, 
24,595 in-frame and frame-shift deletions such as chr3:g.137843433_137843435del 
and chr19:g.58863869_58863869del, and 166 block substitutions (BLSs) from the 
catalogue of somatic mutations in cancer (COSMIC v67). BLS represents in-frame 
	  33	  
or frame-shift replacements that potentially incorporate both insertion and deletion in 
one event, such as chr5:g.112175419_112175425delinsGCA and 
chr7:g.55249018delinsAACCCCT.  
        We used the genomic and corresponding protein variants reported in COSMIC 
as the ground truth for this comparison. The ground truth here was clearly subject to 
any annotation biases when variants were submitted to COSMIC. Differences from 
the ground truth largely indicate inconsistency among annotators or rules used 
(instead of correctness in any absolute sense). Although TransVar can jointly utilize 
multiple transcript databases in annotation, we tried to use a consistent one for our 
comparison in Table S2.1. Specifically, TransVar (version 2.1.15.20150827), 
ANNOVAR (released on 2015Mar22), VEP (version 81) and snpEff (version 4.1) 
used Ensembl v75, while Oncotator (version 1.5.1.0) used GENCODE v19. Minor 
differences may exist among the instances of databases used by these tools. We 
used the default settings of each tool. We considered one genomic variant as being 
annotated consistently with COSMIC if the results reported by an algorithm contain 
the corresponding entry in COSMIC, as each algorithm may output multiple 
annotation entries for a given genomic variant, due to alternative isoform usages. 
For all types of variants, we required that the gene name, protein coordinate and 
reference amino acid match exactly with those in COSMIC. 
        For SNSs, ANNOVAR, VEP, Oncotator and snpEff achieved similar results with 
around 92% consistencies. TransVar achieved slightly higher consistency at 96% 
(Figure 2.2 and Table S2.1). Since the forward annotation algorithm in TransVar did 
not have major differences from others, such difference in consistency may be 
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attributed to minor differences in the databases used or other implementation 
details. The small percentage (4%) of SNSs that TransVar failed to annotate 
consistently was due mostly to invalid or imprecise use of gene names (e.g., ANXA8 
for ANXA8L2) or missing matched transcript definitions (e.g., unmatched reference 
alleles at specified coordinates) in Ensembl v75. Thus, TransVar’s forward 
annotation algorithm might have achieved the best possible result in this experiment. 
In addition, we found that the consistency of TransVar dropped to 68.8% if only the 
longest transcripts in Ensembl v75 were selected. This indicated the importance of 
considering all available transcripts in performing annotation to avoid inaccurate 
interpretation. 
 
Figure 2.2 Comparison of forward annotation consistency among TransVar, VEP, 
ANNOVAR, snpEff and Oncotator. Plotted are percentages of variants (Y axis) that had 
matched protein annotations in COSMIC v67 based on 964,132 unique SNSs, 3,715 MNSs, 
11,761 INSs, 24,595 DELs and 166 BLSs (X axis). NA: Protein level annotations not 
available. (Figure reprinted from TransVar: a multilevel variant annotator for precision 
genomics. Wanding Zhou, Tenghui Chen, Zechen Chong, Mary A Rohrdanz, James M 
Melott, Chris Wakefield, Jia Zeng, John N Weinstein, Funda Meric-Bernstam, Gordon B 
Mills, and Ken Chen, Nature Methods, 2015. According to the journal policy, the author 
retains the right to include the published article in full or in part in a dissertation.) 
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         TransVar achieved higher consistency than ANNOVAR, snpEff, Oncotator and 
VEP in annotating insertions, deletions and BLSs, due mainly to its more 
comprehensive support of different indel reporting rules (Figure 2.2 and Table S2.1). 
Most indel variants are reported at 3'-aligned amino acid (AA) positions in COSMIC, 
conforming to the HGVS conventions. However, ANNOVAR, snpEff and Oncotator 
reported them at only the 5'-aligned AA positions, resulting in relatively large extents 
of inconsistency. VEP achieved better consistency because it reported indels at the 
3'-aligned AA positions. TransVar achieved the highest consistency because it 
reported not only 3'-aligned AA positions but also 5'-aligned, as well as unshifted AA 
positions as alternatives. Interestingly, there are some variants for which none of the 
annotators (including TransVar) could produce annotation consistent with COSMIC. 
For example, chr11:g.32417943_32417943delinsGGG, which was annotated as 
WT1:p.302 in COSMIC, was consistently annotated as WT1:p.121, p.141, p.158, or 
p.370 by TransVar, snpEff, Oncotator and VEP, suggesting some transcripts that 
generated the original annotations in COSMIC have become obsolete in Ensembl 
v75 or GENCODE v19. 
         The above findings of the annotation inconsistencies between TransVar and 
other variant annotators can largely be attributed to a lack of standardization among 
variant annotations (codon or AA positions of variants) submitted to COSMIC and 
among conventions implemented in various annotators. Inconsistency in annotations 
blurred the lines of evidence for variant frequency estimation and led to inaccurate 
determination of variant function. TransVar revealed hidden inconsistency in these 
variant annotations by comprehensively outputting alternative annotations in all  
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Figure 2.3 Comparison of forward annotation consistency between COSMIC and TCGA 
mutation data using TransVar. The datasets were investigated in several different ways: (A) 
using all the available mutations, (B) using all the point mutations (including missense, 
nonsense and silent mutations), and (C) using all the indel mutations. 
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available transcripts in standard HGVS nomenclature, and thus resulted in greater 
consistency in this experiment. 
2.2.3 Forward annotation ambiguities in TCGA and COSMIC mutation data 
         Beside the annotation ambiguities that exist when using different transcript 
databases or different database versions, we also found a large inconsistency of 
annotation among various data sources such as TCGA and COSMIC. To specifically 
investigate the forward annotation inconsistency between TCGA and COSMIC, we 
thoroughly compared the annotation datasets from TCGA and COSMIC in 19 cancer 
types. In Figure 2.3A, in the majority of the investigated cancer types, the 
inconsistency rate was above 10%, which means more than 10% of the genomic 
variants shared by TCGA and COSMIC were actually annotated to different protein 
variants. To further investigate the ambiguities from different types of mutations, we 
dissect the mutation sets into SNV and indels.  
       In Figure 2.3B, we found most of the inconsistency rates of SNV annotation 
were a bit lower than 10%, while in Figure 2.3C, we found most of the inconsistency 
rates of indel annotation were higher than 10%. The results indicated that indels 
overall have a higher annotation ambiguity as compared to SNVs. As we explained 
above, this might be due to the more complex rules implemented when annotating 
indels, such as alignment options. 
2.2.4 Forward annotation of RNA-editing sites by TransVar 
        Recent studies indicate that RNA-editing contributes to human disease, 
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including cancer [81, 82]. RNA-editing sites are typically discovered by comparing 
matched RNA-seq and DNA-seq reads based on their alignment to a common 
genomic reference [83]. However, the functional interpretation of resulting RNA-
editing sites may be ambiguous due to lack of clarity about the isoform used. For 
example, an RNA-editing site in the coding region of one isoform may be in a UTR 
region of another. To quantify the extent of such ambiguity in current RNA-editing 
studies, we downloaded a set of 1,379,403 curated A-to-I RNA-editing sites [83]. 
Using TransVar, based on the human reference assembly GRCh37 and Ensembl 
v75 transcript database, we found that 401,146 (29.8%) sites could affect different 
regions on different isoforms. For example, chr12:g.69237552 could affect the 
coding region of exon 1 or exon 2, the 3ʹ-UTR, or the intronic region between exons 
5 and 6 of various isoforms of MDM2. TransVar also revealed many sites such as 
chr3:g.126299981 and chr6:g.43585896 that could be annotated as either in an 
intronic region or in the UTR, whereas the original annotation reported only one of 
the possibilities [83].  
2.2.5 Reverse annotation accuracy for SNV, indels and frame-shift variants 
        TransVar’s novel reverse annotation can be used to ascertain if two protein 
variants have an identical genomic origin, thus reducing inconsistency in annotation 
data. It can also reveal whether or not a protein variant has non-unique genomic 
origins and requires caution in genetic and clinical interpretation. We evaluated 
TransVar’s reverse annotation accuracies of single amino acid substitutions (SASs), 
amino acid insertions (INSPs), deletions (DELPs) and frame-shift substitutions 
(FSPs) in various databases.  
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         For SASs, given a protein variant, the accuracy was calculated based on 
whether the position of the genomic variants inferred by TransVar contains the one 
that was reported in COSMIC. Using the Ensembl database v75 (Table 2.1), we 
found 91.8% of the SASs protein variants in COSMIC can be accurately traced back 
to the genomic variants by using TransVar’s reverse annotation. Among those 
SASs, only 79.8% of the SASs protein variants can be uniquely traced back to the 
genomic variants by using TransVar reverse annotation, the remaining 12% have 
multiple genomic mapping positions because of different transcript isoform usages. 
We also tried to estimated the reverse annotation accuracies using the RefSeq v105 
and CCDS v37.3 databases, the consistencies and uniqueness of reverse 
annotation were different from what has been observed using Ensembl database 
v75 (Table 2.1). In addition, we tried to combine the above-mentioned three 
databases, and found that the consistency was improved to 94.7% while the 
uniqueness was dropped to 74.7% due to redundant transcript isoforms that are 
used in different transcript databases. 
         For INSPs, DELPs and FSPs, We regarded that a reverse annotation reported 
by TransVar was consistent if the genomic start position of the annotated variant 
was within 5 bp of the original genomic start position in COSMIC. Uniquely mapping 
INSP, DELP and FSP to genomic coordinates was much more challenging than 
SASs and sometime impossible due to repeats, which resulted in lower consistency 
in these variant types (Table 2.1). For example, an insertion of a glutamine (Q) into 
any location in a five-glutamine peptide usually results in a notation of the insertion 
before the first glutamine following the reporting rule of 5ʹ-alignment (Figure S2.1).  
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Table 2.1 Reverse annotation consistency of COSMIC protein identifiers via different 
transcript databases 
 
 
  Ensembl RefSeq CCDS Merged* 
SAS 
Uniquely 79.8% 81.0% 85.8% 74.2% 
Consistently 91.8% 88.6% 88.0% 94.7% 
INSP 
Uniquely 74.4% 74.7% 75.6% 73.8% 
Consistently 75.6% 75.7% 76.0% 75.8% 
DELP 
Uniquely 68.4% 75.2% 64.7% 65.8% 
Consistently 87.6% 87.3% 83.9% 87.9% 
FSP 
Uniquely 44.0% 45.1% 47.7% 41.7% 
Consistently 50.9% 49.2% 48.8% 55.8% 
 
 
*The merged database contains all the transcripts in Ensembl v75, RefSeq (release 105) 
and CCDS (NCBI release 37.3) databases. A variant is called “consistently” annotated if its 
reverse-annotation result contains the matched original genomic identifier from COSMIC, 
and “uniquely” annotated if its reverse-annotation result matched uniquely with the genomic 
identifier in COSMIC (allowing ±5 bp positioning ambiguity). (Table reprinted from TransVar: 
a multilevel variant annotator for precision genomics. Wanding Zhou, Tenghui Chen, Zechen 
Chong, Mary A Rohrdanz, James M Melott, Chris Wakefield, Jia Zeng, John N Weinstein, 
Funda Meric-Bernstam, Gordon B Mills, and Ken Chen, Nature Methods, 2015. According to 
the journal policy, the author retains the right to include the published article in full or in part 
in a dissertation.) 
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Using the Ensembl database v75, we found 75.6% of INSPs, 87.6% of DELPs and 
50.9% of FSPs in COSMIC can be accurately traced back to the genomic variants 
by using TransVar reverse annotation. Among those variants, 74.4% of INSPs, 
68.4% of DELPs and 44.4% of FSPs can be uniquely traced back to the genomic 
variants by using TransVar reverse annotation, the remaining variants have multiple 
genomic mapping positions because of different transcript isoform usages. Similar to 
what have been investigated in SASs, we also tried to estimated the reverse 
annotation accuracies on INSPs, DELPs and FSPs using RefSeq v105 and CCDS 
v37.3 databases, the consistencies and uniqueness of reverse annotation were 
different from what has been observed using Ensembl database v75 (Table 2.1). 
When combining the three transcript databases, the consistency was much 
improved while the uniqueness rate was further dropped due to redundant transcript 
isoform usages. 
         Besides the different consistencies that were observed using different 
transcript databases in an identical mutation types. We consistently found that 
insertions have a lower fraction of unique mapping compared with deletions. This is 
because of the lack of a reference allele that can be used to constrain the search 
scope of transcripts. For example, ABCA5:c.742_743insA does not contain 
reference bases to constrain the search whereas a deletion 
ABCA10:c.1328_1331delTGTC, contains “TGTC” which provides the deleted 
reference bases to constrain the search. Insertions on the protein level are less 
affected since the first and the last amino acids are usually specified in the identifier 
(e.g., ACIN1:p.S647_A648insRS), which enables TransVar to include reference  
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Table 2.2 Reverse annotation consistency of COSMIC mRNA identifiers via different 
transcript databases 
 
 
  Ensembl RefSeq CCDS Merged* 
SNS 
Uniquely 63.7% 73.2% 89.7% 49.1% 
Consistently 95.5% 92.3% 91.8% 97.3% 
INSN 
Uniquely 24.1% 34.1% 60.5% 11.9% 
Consistently 81.0% 78.3% 77.9% 85.1% 
DELN 
Uniquely 61.0% 66.2% 80.2% 50.5% 
Consistently 90.5% 87.2% 86.9% 93.9% 
BLSN 
Uniquely 78.0% 80.2% 86.4% 71.9% 
Consistently 92.0% 89.7% 88.8% 95.3% 
 
 
*The merged database is a combination of Ensembl v75, RefSeq (release 105) and CCDS 
(NCBI release 37.3). A variant is called “consistently” annotated if its reverse-annotation 
result contains the matched genomic identifier in COSMIC, and “uniquely” annotated if its 
reverse-annotation result exactly matched the genomic identifier in COSMIC (allowing ±5 bp 
positioning ambiguity). (Table reprinted from TransVar: a multilevel variant annotator for 
precision genomics. Wanding Zhou, Tenghui Chen, Zechen Chong, Mary A Rohrdanz, 
James M Melott, Chris Wakefield, Jia Zeng, John N Weinstein, Funda Meric-Bernstam, 
Gordon B Mills, and Ken Chen, Nature Methods, 2015. According to the journal policy, the 
author retains the right to include the published article in full or in part in a dissertation.) 
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alleles to narrow the search scope and reduce the ambiguity.  
        Furthermore, we also investigated the reverse annotation performance of 
TransVar using the cDNA variants. Similar to what has been observed using the 
protein variants, a large number of inconsistencies were observed using different 
types of variants and different transcript databases (Table 2.2). 
2.2.6 Reverse annotating protein phosphorylation sites using TransVar 
        TransVar’s novel reverse annotation functionality can greatly facilitate 
identification of the genomic origins of variants that are functionally interesting at 
protein or mRNA levels, such as those identified from mass spectrometry data. For 
example, identifying the genomic locations of phosphorylation sites (such as 
p.Y308/p.S473 in AKT1 and p.Y1068/p.Y1172 in EGFR) can lead to the recognition 
of DNA variants that affect phosphorylation-mediated signal transduction, a 
biological process central to current pharmacogenomics research. Translation from 
a protein (e.g., EIF4ENIF1:p.Y580) to a genomic identifier 
(chr22:g.31845362_31845364) usually involves a tedious manual process that is not 
scalable. First, the UniProt ID must be mapped to a transcript ID. Then, a sentinel 
site with a known protein-level coordinate must be identified to enable one to 
measure the distance from the desired site to the sentinel site and step the 
corresponding number of amino acids. That process must be repeated for all of the 
isoforms until a matching reference amino acid is identified. With TransVar, all of 
those processes are automated. As a demonstration, we downloaded and analyzed 
191,903 sites of protein phosphorylation in human proteins from PhosphoSitePlus 
	  44	  
[84]. In just a few minutes of compute time, we were able to map 167,696 sites 
(87.4%) to genomic coordinates using CCDS transcripts and 187,464 (97.69%) sites 
using a combined transcript definition from CCDS, Ensembl and RefSeq. Most of the 
mapping failures were attributable to obsolete UniProt identifiers that were no longer 
present in the current releases. 
2.2.7 Impact of TransVar on designing experimental validation 
         In clinical genetics and translational genomics investigations, frequently only 
the protein variant information is provided to the biological researchers. However, it 
is critical to know the genomic information of the specific protein variant to allow for 
precise experimental validation to show the exact function of the variant. For 
example, FGFR2:p.N549K is a protein variant from FGFR2, which is known to be an 
oncogene that promotes cell proliferation, however, the specific role of FGFR2: 
p.N549K is still unknown. It is important for the researchers to know the 
chromosomal and cDNA locations of this protein variant, then the genomic and 
transcriptomic information can be used to implement a specific mutation on the wild-
type FGFR2 transcript and investigate the functional consequences through in vitro 
and in vivo experiments. Therefore, a tool that is capable of performing reverse 
annotation from protein to genomic level would be highly desired. With this 
motivation, we implemented the reverse annotation function of TransVar. In this 
case, TransVar could efficiently take FGFR2:p.N549K as an input and output all 3 
potential genomic variants along with their corresponding transcript identifiers (Table 
2.3). Given the results provided by TransVar, the users will be able to fully capture 
the potential ambiguities in annotating the specific variant and obtain the necessary 
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information to design the experiments. 
        Given the truth that we observed large ambiguities in both forward and reverse 
annotations due to different transcript isoform usages, we investigated 537 clinically 
actionable protein variants and found that 78 (14.5%) could be annotated to multiple 
genomic origins (Table 2.4), indicating the criticalness of using a reverse annotation 
tool such as TransVar to resolve such ambiguities in clinics. 
 
Table 2.3 Reverse annotation results of FGFR2:p.N549K using TransVar 
 
 
Input Transcript Coordinate Region 
FGFR2:p.N549K ENST00000357555 chr10:g.123247577A>C/c.1647T>G/p.N549K Exon 13 
FGFR2:p.N549K ENST00000358487 chr10:g.123258034A>C/c.1647T>G/p.N549K Exon 12 
FGFR2:p.N549K ENST00000360144 chr10:g.123247580G>C/c.1647C>G/p.N549K Exon 13 
 
2.2.8 Impact of TransVar on Pharmacogenomics and hotspot mutation 
prediction 
         Another application of TransVar lies in clinical pharmacogenomics and 
functional mutation prediction.  
         When performing clinical treatment decision-making using genetic biomarker 
status, frequently the clinicians just use the protein variant information to make a 
treatment decision. However, due to the fact that a genomic variant that is 
discovered in a patient could potentially be annotated to different protein variants 
because of multiple transcript isoform usages, an ambiguity in using the protein 
variant as the biomarker could come up and potentially lead to incorrect treatment 
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decision making. For example, EGFR:p.T790M is a well known biomarker that 
indicates resistance to Tyrosine kinase inhibitor (TKI) treatment [85-87]. In the 
COSMIC dataset, EGFR:p.T790M (ENST00000275493) is frequently observed. 
However, this protein variant is absent in the TCGA dataset. When we investigate 
the genomic origin of this protein variant in COSMIC, it corresponds to 
chr7:g.55249071C>T, but if we trace this genomic variant chr7:g.55249071C>T in 
TCGA, it was actually annotated to EGFR:p.T745M (ENST00000455089) because 
of different transcript isoform usage (Figure 2.4A). Therefore, based on the 
annotation that was performed in TCGA, the biomarker indication could be missed. 
With the equivalence annotation function of TransVar, we were able to infer that 
EGFR:p.T745M is actually an equivalent protein identifier for EGFR:p.T790M. By 
this manner, even if EGFR:p.T745M is observed in a clinical genetic report, the 
clinicians could still link it to EGFR:p.T790M and know that the patient may have 
drug resistance to TKI treatment. 
        It is common for a variant and its functional consequence to be described 
based on protein level information, such as hotspot mutations. However, due to the 
fact that a genomic variant that is discovered in a patient could potentially be 
annotated to different protein variants because of multiple transcript isoform usages, 
an ambiguity could be observed when try to define a hotspot mutation and 
investigate its functional consequence based on the protein variant information. For 
example, EGFR:p.A244T (ENST00000455089) is a hotspot mutation that was 
detected in the TCGA dataset. However, this variant is absent in the COSMIC 
dataset. When we try to figure out the genomic origin of this protein variant in TCGA,  
	  47	  
Table 2.4 Clinically actionable cancer mutations with non-unique genomic origins 
 
 
Protein Identifier # of Possible Genomic Origins PMID 
CDKN2A:M53_R58del 9 11255261 
CDKN2A:R87P 6 12352668 
ERBB2:L755_T759del 5 23220880 
ERBB2:774_775insAYVM 5 16843263|19122145 
CDKN2A:A36P 3 11595726 
CDKN2A:L63V 3 11255261 
FGFR1:N546K 3 21367659|15509736|16186508 
EGFR:L747_S752del 3 18981003 
EGFR:E746_A750del 3 16373402|15837736|17318210 
AKT1:P42T 3 23134728 
FGFR2:G227E 3 19147536 
FGFR2:N549H 3 17525745 
FGFR2:N549K 3 22383975|17525745 
PTCH1:P681L 2 | 
PTCH1:Q688* 2 | 
CDKN2A:A57V 2 19260062 
CDKN2A:R58* 2 12362978|11255261 
CDKN2A:W110* 2 11255261 
CDKN2A:E69* 2 8668202 
CDKN2A:P114S 2 23190892 
CDKN2A:P114L 2 7777061|8755727 
CDKN2A:R80* 2 8668202 
CDKN2A:R124fs*22 2 11255261 
ABL1:V299L 2 23086624|19201023|21509757 
ABL1:E255V 2 20038234|15293570|19164531|21505103 
ABL1:E255K 2 12663457|12692682|20697894|19768693 
ABL1:L248_K274del 2 17008892|21221851|18354488 
ABL1:L184_K274del 2 18354488 
EGFR:L838V 2 19147750 
EGFR:H835L 2 21422421 
EGFR:G810S 2 19147750 
EGFR:L747S 2 17973572 
EGFR:E709G 2 16205628 
EGFR:E709A 2 19671738 
EGFR:E709K 2 19726454 
EGFR:A702S 2 19020901 
EGFR:R521K 2 | 
BRAF:T241P 2 19206169 
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KIT:D816V 2 7691885|7512180|23777495|19718013 
KIT:D816A 2 16188233|22847983 
KIT:D816F 2 9990072 
KIT:D816I 2 19865100 
KIT:D816Y 2 21504297|19698218|9990072 
KIT:D816H 2 21504297|14695343|16188233 
KIT:D579del 2 12727838|9797363 
KIT:V559_V560del 2 9797363|9438854 
KIT:V559del 2 9989791 
KIT:W557_K558del 2 12727838|12918066|16203282 
KIT:Y553_Q556del 2 9438854|12727838 
KIT:M552_Y553del 2 12727838 
KIT:P551_V555del 2 11719439|12727838|9438854 
KIT:K550_K558del 2 15824741|12727838 
PIK3CA:G118D 2 23246288|22949682 
ERBB2:V842I 2 23220880 
ERBB2:L755S 2 16397024|18413839|23220880 
ERBB2:R896C 2 23220880 
ERBB2:T733I 2 16397024|18413839 
AKT1:R25C 2 23246288|8702995|18823366|17138652 
AKT1:Q79K 2 23134728 
AKT1:D32Y 2 23134728 
AKT1:E17K 2 17611497|23134728|23888070 
AKT1:L52R 2 23134728 
AKT1:T435P 2 23246288 
FLT3:I836del 2 | 
FLT3:I836del>MN 2 12036858|12663439 
CDK4:K22Q 2 9426066|9228064|9712735 
CDK4:K22R 2 22197931|9228064|9426066|9712735 
CDK4:K22M 2 9228064|9426066|9712735 
KRAS:F156L 2 17875937 
KRAS:R164Q 2 20147967 
PTEN:L181P 2 21828076 
PTEN:V166I 2 21828076 
PTEN:Q171A 2 21828076 
PTEN:S170R 2 21828076|10866302 
PTEN:C105F 2 19644652|10560660|10866302 
PTEN:K13E 2 14711368 
FGFR2:K659E 2 22383975|17525745|23527311 
FGFR2:K659N 2 23527311|17525745 
 
PMID: PubMed IDs of the publications that indicate the clinical actionability of mutations. 
Ensembl v75 and GRCh37/hg19 assembly were used to obtain this result. 
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Figure 2.4 Inconsistent forward annotation in TCGA and COSMIC. (A) chr7:g.55249071C>T 
was annotated to EGFR:p.T790M using transcript isoform ENST00000275493 in COSMIC 
while it was annotated to EGFR:p.T745M using transcript isoform ENST00000455089 in 
TCGA. (B) chr7:g.55221821G>A was annotated to EGFR:p.A244T using transcript isoform 
ENST00000455089 in TCGA while was annotated to EGFR:p.A289T using transcript 
isoform ENST00000342916 and ENST00000344576 in COSMIC. 
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it corresponds to chr7:g.55221821G>A, but if we track this genomic variant 
chr7:g.55221821G>A in COSMIC, it was actually annotated to EGFR:p.A289T 
(ENST00000342916 and ENST00000344576) because of different transcript isoform 
usage (Figure 2.4B). As a result, based on the inconsistent annotations that were 
used in COSMIC and TCGA, the frequency of EGFR:p.A244T/EGFR:p.A289T can 
be largely underestimated. In addition, some potential hotspot mutations may be 
missed due to this type of annotation inconsistencies within a single mutation cohort 
or across different mutation cohorts. With the equivalence annotation function of 
TransVar, we were able to infer that EGFR:p.A289T is actually an equivalent protein 
identifier for EGFR:p.A244T. In this way, we would be able to recover the frequency 
of observed protein variants and correctly classify their functionalities. 
2.2.9 Web interface of TransVar 
 
Figure 2.5 The web interface of TransVar that shows how to perform reverse 
annotation and what type of information could be obtained from the output. 
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Figure 2.6 A screenshot of the homepage of TransVar. It provides detailed information of 
obtaining the source code, installing TransVar and running examples of different annotation 
functions. 
 
 
 
 
	  52	  
To allow for easy usage of TransVar, we developed a web interface 
(www.transvar.net), in which the users are free to perform different types of 
annotation (forward, reverse and equivalence annotation) using different reference 
genomes and different transcript databases. Currently we support human reference 
genome hg18, hg19 and hg38 as well as all available transcript databases that 
correspond to each reference genome. For example, when performing the reverse 
annotation, the user could choose ‘Reverse annotation: Protein’ as the annotation 
option followed up any specific reference genome and any available transcript 
database, and the results will output all the available genomic variants along with 
their corresponding transcript identifiers of the given protein variant (Figure 2.5). 
2.2.10 Command line usage of TransVar 
        In addition to the web interface, we also provide a command line tool for batch 
analysis. On the homepage of TransVar (Figure 2.6), we provide detailed 
instructions of how to obtain the source code and how to install TransVar on the 
user’s machine, and a bunch of examples to run different types of annotations of 
TransVar, such as forward, reverse and equivalence annotation. 
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2.3 Discussion 
        We developed TransVar, which is a comprehensive variant annotator that 
performs multi-level variant annotation such as forward annotation from genomic to 
RNA and to protein level, and reverse annotation from protein to RNA and to 
genomic level. We developed TransVar as a web-based bioinformatics tool to 
enable the complete and accurate characterization of the origin and functionality of 
genomic variants identified by the research community. 
        Using TransVar, we have identified frequent ambiguities in the current 
transcript databases (such as Ensembl, RefSeq and CCDS) available for basic and 
translational research. These include ambiguities in translation among genomic, 
cDNA and protein levels that involve cancer hotspot mutations, biomarkers that 
affect clinical treatment decision-making, potentially clinically actionable variants, 
protein phosphorylation sites and RNA-editing sites. With TransVar, we were able to 
(i) pinpoint such ambiguities efficiently; (ii) associate variant identifiers accurately 
across genomic, cDNA and protein levels; and (iii) achieve unambiguous data 
exchange across different sources.  
        Our results indicated an urgent need to standardize variant annotation and to 
improve the quality of information technology that implements the standards. It is not 
sufficient to specify only the variants themselves; the isoforms that have been used 
in annotation must also be specified completely in variant databases, and the 
information must be included in data-sharing processes.   
         One important application of TransVar lies in revealing all the potential 
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genomic origins of a given protein variant. In our current study, we have focused on 
somatic mutations in cancer and have created lists and tables that are useful for 
disambiguating clinically actionable mutations. Similar lists and tables can be 
created for other diseases using TransVar to ensure accurate use of information for 
clinical decision support, genetic diagnosis and counseling.  
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CHAPTER 3 
 
Hotspot mutations delineating diverse mutational signatures and 
biological utilities across cancer types 
 
 
(Most of the methods and results in this chapter have been accepted for a 
publication in BMC Genomics: Tenghui Chen, Zixing Wang, Wanding Zhou, 
Zechen Chong, Funda Meric-Bernstam, Gordon B Mills, and Ken Chen, 
“Hotspot mutations delineating diverse mutational signatures and biological 
utilities across cancer types”. The manuscript is currently in final 
proofreading and not online yet.) 
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3.1 Materials and Methods 
3.1.1 COSMIC somatic mutation data 
        We downloaded the COSMIC somatic mutation dataset version 71 for our 
study. As introduced in the COSMIC data source, this total mutation set (12250 
samples) includes many sources of curated mutation data. We excluded samples 
that underwent targeted-sequencing [88], and selected only those that were 
subjected to either whole genome or whole exome sequencing (Table S3.1). In this 
manner, we ensured that all the exons of investigated genes were uniformly 
examined in the selected samples.  
3.1.2 Cancer gene candidates 
        We collected a set of candidate cancer genes from the literatures, which 
included 546 genes reported in cancer gene census [89], 435 genes in Pancan12 
[90], and 221 genes reported in Lawrence et al [91]. For OncodriveCLUST [49] and 
e-Driver [50], we applied their algorithms to predict tumor type-specific driver genes 
using COSMIC v71 mutation data. We used q-value<0.01 and q-value<0.05 to 
determine driver genes in OncodriveCLUST and in e-Driver, respectively.  
3.1.3 Definition of hotspot mutations 
        Our algorithm identifies hotspots based on amino acid (AA) positions (Figure 
3.1). To make sure we have an adequate count of mutations, five major mutation 
types were included in our statistical modeling: missense, nonsense, coding-silent, 
insertion and deletion. For missense, nonsense and coding-silent mutations, six 
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types of di-nucleotide sequence context were considered: A/T transition (ATts), A/T 
transversion (ATtv), CpG island G/C transition (CpG_CGts), non-CpG island G/C 
transition (NoCpG_CGts), CpG island G/C transversion (CpG_CGtv), non-CpG 
island G/C transversion (NoCpG_CGtv), as previously introduced [47]. Altogether, 
20 mutation subtypes were considered (Table S3.2). For each mutation subtype in 
each gene, we counted the number of subtype-specific mutations across all the 
samples. For each gene, we calculated the mean subtype-specific mutation rate as 
the total number of subtype-specific mutations in the coding regions (E) divided 
(normalized) by the protein length. We calculated a p-value based on the number of 
observed subtype-specific mutations (O) in a given AA, assuming the number of 
mutations in each mutation subtype follows a Poisson distribution. After obtaining a 
p-value for each mutation subtype, we computed an integrated p-value for each AA 
based on Fisher’s method [92] 
𝑥 = −2 𝑙𝑜𝑔(𝑝𝑜𝑖𝑠(𝑂! ,𝐸!))!!!! , 
where 𝑖 represents a mutation subtype, and 𝑝𝑜𝑖𝑠 the Poisson distribution; 𝑥 follows a 
chi-square distribution with 2𝑘 degrees of freedom, where 𝑘 is the number of 
mutation subtypes tested. We further applied false discovery rate (FDR) correction 
[93] and reported hotspot mutations in AA positions with adjusted p-value < 0.001 in 
COSMIC.   
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Figure 3.1 A schematic overview of HotDriver. Providing a mutational profile from a 
specific tumor type, the variants were classified into 20 mutation subtypes, then the mutation 
subtype-specific mutation rates were computed for each investigated gene and the 
significance level of each amino acid position in the corresponding gene was calculated. 
After that, the significance level of each amino acid position was calculated by combining p 
values from different mutation subtypes using Fisher’s method, and an adjusted p value was 
computed for each amino acid position. 
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3.1.4 TCGA pan-cancer data 
        We downloaded TCGA pan-cancer level-3 somatic mutation, copy number 
alteration and RNA expression data from Synapse 
(https://www.synapse.org/#!Synapse:syn300013) as last updated in November 
2014, and RPPA data from TCPA 
(http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html) [94] for 
19 cancer types. More than 4400 tumor samples were assayed by whole exome 
sequencing, total RNA sequencing [95], or reverse phase protein array (RPPA) 
technologies. The number of tumor samples available for each cancer type is listed 
in Table S3.3. In terms of copy number alterations, we called deletions where the 
normalized copy number value is less than -1 and amplifications where the value is 
greater than 1. In terms of RNA expression data, we used the normalized TCGA 
level-3 RNA expression data in our study. To allow for log transformation, the RPKM 
values of 0 were set to the minimum nonzero RPKM in the given samples. We 
applied log2 transformation to all mRNA RPKM expression values, as described by 
Jacobsen et al. [96]. In terms of protein expression data, we analyzed the 
expression level of 181 proteins in total using RPPA, which contains 181 high-quality 
antibodies targeting 128 total proteins and 53 post-translationally modified proteins. 
We used the normalized level-3 RPPA data (level-4 data for Breast invasive 
carcinoma) in our study [94]. 
       To test associations between mutations and RNA expression, we used samples 
that had both somatic mutations and RNA expression data available. To test 
associations between mutations and protein expression, we used samples that had 
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both somatic mutation and RPPA data available (Table S3.3).  
3.1.5 Cancer Cell Line Encyclopedia (CCLE) mutation and drug sensitivity data  
        The CCLE [71] contains drug activity data for 24 different compounds in 504 
cell lines and somatic mutation data of 906 cell lines. In our analysis, we included 
cell lines with both drug sensitivity and mutation data. Drug sensitivity data were fit 
using a logistical-sigmoidal function and described by 4 different variables: the 
maximal effect level (Amax), the drug concentration at half-maximal activity of the 
compound (EC50), the concentration at which the drug response reached an 
absolute inhibition of 50% (IC50), and the activity area, which is the area above the 
dose-response curve [71]. In our analysis, we used the activity area (the under curve 
area), which captures both efficacy and potency of drug activity according to the 
CCLE, to measure drug responses.  
3.1.6 Tumor-type prevalence of hotspot mutations 
        To measure the prevalence of a hotspot mutation in tumor type A, we 
calculated the number of A samples that contain a target mutation B, the number of 
A samples that do not contain B, the number of non-A samples that contain B, and 
the number of non-A samples that do not contain B, respectively (Table S3.4). Then 
we used Fisher’s exact test to compute the significance and applied an FDR 
correction. A hotspot is considered to be highly prevalent in a specific tumor type if 
the adjusted p-value < 0.01. 
3.1.7 Conservation score comparison  
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         We downloaded the chromosomal base-wise Genomic Evolutionary Rate 
Profiling (GERP) scores computed by GERP++ [97]. In our study, we extracted the 
resistant substitution (RS) scores from the nucleotide bases that belong to hotspot 
mutations and that belong to non-hotspot mutations, and tested if the scores 
between these two groups were significantly different. A higher RS score represents 
stronger evolutionary conservation. 
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3.2 Results 
3.2.1 Variable mutation rates among different tumor types and mutation 
subtypes 
         As mentioned previously in the methods, we classified all the mutations into 20 
subtypes based on both mutation types and di-nucleotide sequence contexts (Table 
S3.2). In the COSMIC mutation dataset, skin, stomach, bladder and colon tumors 
have relatively high overall mutational rates, which were consistent with a previous 
report [48]. Besides, we also observed high mutational rates in bone and 
endometrium tumors (Figure 3.2). However, we observed highly variable mutational 
rates across different mutation subtypes (Kruskal-Wallis H-test, p=2.22e-05). In one 
tumor type, different mutation subtypes have largely inconsistent mutational rates. 
For example, in bone tumors, nonsense non-CpG C/G transversion has a mutation 
rate of 0.69/Mb while nonsense CpG C/G transition has a mutation rate of 14.2/Mb. 
In skin tumors, missense non-CpG C/G transition has a mutation rate of 6.18/Mb 
while silent AT transversion has a mutation rate of 0.53/Mb. Similarly, the mutational 
rate of one mutation subtype can vary substantially across different tumor types 
(Kruskal-Wallis H-test, p=3.49e-40). For example, missense non-CpG C/G transition 
has an average rate of 6.18/Mb in skin tumors, much higher than in brain tumors 
(0.61/Mb). Therefore, to identify potential drivers that are positively selected in 
cancer, it is important to account for mutation rate variations among mutation 
subtypes and sequence contexts in different tumor types, instead of assuming an 
uniform background mutation rate and examining only variant frequencies in the 
population. 
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Figure 3.2 Statistics of the mutation distribution in different tumor types in COSMIC. 
The mutation rate of 20 mutation subtypes in 17 main tumor types of COSMIC v71 whole 
genome and whole exome sequencing data. 
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3.2.2 Identifying hotspot mutations in COSMIC 
        We started with all the mutations in 17 tumor types in COSMIC v71 (Figure 
3.3). Only data that were obtained via either whole exome or whole genome 
sequencing were used (Methods, Table S3.1) [88]. Estimation of background 
mutation rates may be biased by outlier hyper-mutated samples. To avoid such bias, 
we calculated the mean µ and the standard deviation σ of the number of mutations 
in each sample, labeled the samples with numbers of mutations greater than µ + 2σ 
as hyper-mutated, and excluded them from further consideration (Table S3.1).  
        Our goal was to identify hotspot mutations within individual genes (Methods) 
and to explore their potentially biological utilities under different biological and 
disease contexts. The large number of samples in COSMIC made it possible to 
reliably estimate a background mutation rate for each gene in each tumor type and 
mutation subtype (Methods). We identified a hotspot mutation as the set of genomic 
aberrations that affect an amino acid (AA) position and occur significantly more 
frequently than expected from the background. In total, we identified a set of 702 
putative hotspot mutations in 549 genes in 17 tumor types (Figure 3.3, Methods).  
         We measured the composition of different mutational subtypes in the hotspot 
mutations (Figure S3.1). As expected, 510 (72.65%) were missense and 17 (2.42%) 
were nonsense, occupying a high proportion of hotspot mutations. We also identified 
31 insertion (4.42%) and 78 deletion (11.11%) hotspots, which were largely ignored 
in previous studies [49, 50] and potentially offer novel candidates for driver mutation 
and cancer gene prediction. Besides, we examined the insertion and  
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Figure 3.3 Illustration of hotspot mutation definition and functional utility analysis. We 
used COSMIC v71 data as the input. We first selected the samples that were examined with 
whole genome or whole exome sequencing, and then removed the hyper-mutated samples 
in each tumor type. Hotspot mutations were identified in individual tumor types, and the 
biological utility investigations were performed. 
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deletion hotspots and found that 17/31 were in-frame insertions and 17/78 were in-
frame deletions. Among the remaining frame-shift insertion and deletion hotspots, 
more than 70% have slightly different start positions and/or sizes. For example, the 
ESRP1 N512 hotspot deletion has two genomic variants chr8:95686611A/- and 
chr8:95686611-95686612AA/-. 
3.2.3 Evaluate the performance of hotspot mutation identification 
        We found that the hotspot-mutation-containing-genes (HMCGs) identified in our 
study overlapped significantly (98/546 vs 451/24405, Fisher exact test, p=1.28e-53) 
with the 546 cancer genes reported in the Caner Gene Census (CGC). Among 
24,951 available genes in COSMIC, 549 genes were identified to contain at least 
one hotspot, among which 98 were the CGC cancer genes. Similarly, we found that 
HMCGs overlapped significantly with the significantly mutated genes reported in 
TCGA PANCAN analysis (101/435 vs 448/24516, Fisher exact test, p=6.56e-74) and 
in Lawrence et al (73/221 vs 476/24630, Fisher exact test, p=2.56e-65). The non-
overlapping genes were detected due likely to that 1) the previous studies had 
different background mutation rate assumptions than our study; 2) they detected 
large numbers of tumor suppressors that do not contain clear hotspot mutations; 3) 
our study was not only able to detect hotspot mutations in known cancer genes, but 
was also capable of detecting hotspot mutations in infrequently mutated genes, 
which may have previously unknown biological functionality; 4) our study included 
mutation types (indels) that previous studies did not. To evaluate the robustness of 
our statistical modeling, we examined the extent of overlap between HMCGs and the 
union of the above mentioned cancer gene sets, and found that the overlap 
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remained highly significant when we chose various adjusted p value cutoffs to 
identify the hotspot mutations (Figure S3.2), which indicated the statistical 
robustness of our approach. 
        Furthermore, we found significantly overlapped genes between our set with 
those predicted by other cluster-based methods such as e-Driver [50] (151/552 vs 
398/24499, Fisher exact test, p=3.42e-139) and OncodriveCLUST [49] (106/489 vs 
443/24462, Fisher exact test, p=2.31e-74). Additionally, regarding the mutational 
clusters, we found 213 hotspots overlapped with 1125 significant mutational clusters 
as identified by e-Driver (213/1125 vs 489/92822, Proportional test, p=2.14e-87) and 
261 hotspots overlapped with 1042 significant mutational clusters as predicted by 
OncodriveCLUST (261/1042 vs 441/89561, Proportional test, p=4.98e-121). Non-
overlapping results were found due mainly to: 1) e-Driver and OncodriveCLUST 
predicted clusters based mainly on missense mutations in a uniform mutational 
background; 2) our study identified not only missense hotspot mutations but also a 
substantial proportion of insertion (4.42%) and deletion (11.11%) hotspots (Figure 
S3.1); 3) our study chose a more stringent statistical significance cutoff to increase 
the confidence of identified hotspot mutations.  
        The number of hotspot mutations varied to a great extent from one tumor type 
to another (Figure 3.4 and Table S3.5). Most tumor types had 5 to 100 hotspot 
mutations. However, colorectal cancer had 253 hotspot mutations despite its 
relatively small sample size (684 samples), including a high proportion of insertion 
(10%) and deletion (23%) hotspot mutations (Figure 3.5). In contrast, only 65 
hotspot mutations were found in myeloid cancer (1,344 samples). Such enrichment  
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Figure 3.4 Number of hotspot mutations defined in individual tumor types using 
COSMIC data. 
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may reflect a higher extent of genetic heterogeneity in the initiation and progression 
of colorectal cancer, as has been suggested previously [98, 99] and also that 
colorectal cancer is predominantly driven by mutations rather than by copy number 
alterations [100]. In addition, we examined the numbers of hotspot mutations and the 
total numbers of mutations (mutation burden) in each tumor type, but did not find a 
clear correlation between them (Figure S3.3). 
3.2.4 Sequence context signature of hotspot mutations 
        We investigated the mutational signatures of 702 hotspot mutations under 
different sequence contexts across different tumor types. As shown in Figure 3.5, in 
7 different tumor types (stomach, ovarian, brain, breast, skin, pancreas and kidney 
cancer), NoCpG_CGts was the most prevalent sequence context compared to other 
sequence contexts under which the hotspot mutations happened (p<0.05), indicating 
a higher strength of positive selection on DNA sequences with NoCpG_CGts 
mutation. In 3 tumor types (head&neck, liver, and myeloid cancer), NoCpG_CGtv 
appears to be the most prevalent sequence context (p<0.05). In several tumor types 
such as brain and ovarian cancer, although NoCpG_CGtv did not act as the 
predominant mutation sequence context, it represented a fairly high percentage 
(brain: 32% and ovarian: 35%). However, in some tumor types such as bladder 
cancer, the hotspot mutations are significantly enriched in ATtv sequence context 
(35%, p=1.77e-2).  
        In terms of the specific sequence context that hotspot mutations occur across 
different tumor types, although insertion is not the most prevalent sequence context  
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Figure 3.5 Mutational signatures of hotspot mutations in 16 tumor types. The x-axis 
represents the tumor types and the y-axis represent the 8 types of sequence contexts 
(concatenating missense, nonsense and silent mutations). Each bar represents the 
percentage of specific sequence contexts under which the hotspot mutations happen. In 
each tumor type, the addition of the percentages of different sequence contexts might be 
larger than 1, because one or more types of mutations may happen on a single hotspot 
driver mutation site. 
 
 
within breast cancer, the percentage of insertion in breast cancer (22%) was 
significantly higher than in any other tumor types (p= 1.14e-02), similarly, the 
percentage of deletion in colorectal cancer (27%) was obviously higher than in other 
tumor types (p=1.84e-4), so as the percentage of ATts (36%, p=5.84e-3) in 
colorectal and ATtv (35%, p=3.73e-3) in myeloid cancer.  
         These observations revealed the common genomic features such as 
NoCpG_CGts and NoCpG_CGtv sequence context that were positively selected 
across various tumor types as well as distinct genomic features that occurred in 
individual tumor types, and highlighted the significance of investigating the hotspot 
mutations under different sequence contexts separately to better understand their 
genetic complexities and functional indications. 
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        To gain a novel functional insight with respect to these mutations that were 
predicted based on statistics of mutation data, we performed a set of additional 
statistical tests to associate these 702 hotspot mutations with functional evidence.  
3.2.5 Exploring the biological utilities of hotspot mutations using TCGA 
mRNA/protein expression data  
        The functional consequences of mutations may manifest in two aspects: 
affecting the expression of the gene containing the mutation or leading to abnormal 
signaling pathway activity. To address these questions, we divided the mRNA and 
protein expression values of a set of TCGA samples into multiple groups based on 
the mutational status of a specific gene in these samples: having a hotspot mutation, 
no hotspot mutation, or no mutations [95]. Only mutations occurring at least twice 
were included in the comparison. Mann-Whitney U tests were performed to measure 
the difference between samples with individual hotspot mutations and samples with 
non-hotspot mutations, as well as between samples with individual hotspot 
mutations and samples without mutation [96]. Among 702 hotspot mutations, we 
found 42 hotspot mutations resulted in significant mRNA or protein expression 
alterations (Table S3.5). 
        It is known that TP53 contains gain of function mutations associated with 
increased expression of TP53 [101, 102] through down-regulation of downstream 
targets such as MDM2/MDM4, which in return attenuate the suppression on the 
expression of TP53. However, it is not well investigated whether different mutations 
in TP53 exhibit different functions across different cancer types. Motivated by this, 
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we examined the association of TP53 hotspot mutations and RNA and protein 
expression of TP53 in different cancer types. To focus on the effect of mutations on 
TP53 expression, we excluded samples harboring TP53 deletions from the analysis 
(Methods). As shown in Figure 3.6A, in breast invasive carcinoma (BRCA), samples 
with R175, R248 and R273 missense mutations have obviously higher mRNA or 
protein expression levels, compared to samples with non-hotspot mutations and with 
no mutation in TP53. In ovarian serous cystadenocarcinoma (OV), similar effects 
were observed for R248 and R273, which are associated with increases in the TP53 
mRNA and protein expressions (Figure S3.4). However, in rectal adenocarcinoma 
(READ), although R175 is associated with increases in TP53 RNA expressions 
similar to what is observed in BRCA, R248 and R273 missense mutations are not 
significantly associated with the TP53 mRNA or protein expression, comparing to 
samples with non-hotspot or no mutations in TP53 (Figure 3.6B), implicating distinct 
functions of R248 and R273 in different disease contexts. In addition, G108 frame-
shift deletion, I195 missense and R213 nonsense mutations, which were uniquely 
detected as hotspot mutations in BRCA, OV and READ respectively, are associated 
with either reduced or enhanced TP53 expression in corresponding cancer types, 
suggesting the functional heterogeneity of hotspot mutations in different cancer 
types (Figure 3.6 and Figure S3.4).  
         Instead of altering the RNA/protein level, certain mutations may function via 
altering downstream protein activity through signaling transduction. For example, 
activation of PIK3CA could lead to activation of downstream targets such as AKT 
phosphorylation [103]. A set of PIK3CA mutations have been detected in various  
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Figure 3.6 Functional implications of hotspot mutations in RNA and protein 
expression. (A) In BRCA, tumor samples with G108 deletion hotspot mutations in TP53 
exhibit lower TP53 RNA expression than those with non-hotspot mutations and without 
TP53 mutations. In contrast, tumor samples with missense hotspot mutations (R175, Y220, 
R248 and R273) in TP53 show higher TP53 RNA and protein expression. (B) In READ, 
tumor samples with R175 missense mutations show higher TP53 RNA and protein 
expression than those with non-hotspot mutations and without TP53 mutations, while R213 
nonsense mutations has the opposite effect. * indicates p<0.05 and ** indicates p<0.001 
between samples with specified hotspot mutations and samples with non-hotspot mutations 
in examined gene; # indicates p<0.05 and ## indicates p<0.001 between samples with 
specified hotspot mutations and samples without mutations in examined gene. 
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cancer types such as BRCA and colon adenocarcinoma (COAD). We examined the 
association of individual PIK3CA mutations and AKT activation by comparing the 
phosphorylated AKT levels in samples with various PIK3CA mutations to those in 
samples without PIK3CA mutation. Surprisingly, in BRCA, only PIK3CA H1047 was 
associated with dramatically higher AKT pT308 and pS473 levels, compared to 
samples that did not have any PIK3CA mutations (Figure 3.7A); in COAD, only 
PIK3CA E542 were associated with significantly higher AKT pT308 and pS473 
levels, compared to samples that did not have any PIK3CA mutations (Figure 3.7B). 
Notably, in both cases, PIK3CA mutations did not affect the total AKT level (data not 
shown), suggesting that different PIK3CA mutations in different cancer types may 
selectively activate AKT via signaling transduction, rather than expression 
regulation. 
         Therefore, the availability of mRNA and protein expression data enable an 
opportunity to characterize the biological consequences of different mutations in one 
cancer type, as well as one mutation under different cancer contexts, reiterating the 
rationale of distinguishing the function of individual mutations in different disease 
contexts.  
3.2.6 Exploring the pharmacogenomics properties of hotspot mutations  
        It has been shown that cancer cells respond to specific drugs when they harbor 
mutations in driver genes such as BRAF and NRAS [53]. However, it is not entirely 
clear whether different mutations in a driver gene can trigger different drug 
responses. Here, we assessed the effects of individual mutations on drug  
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Figure 3.7 Functional implications of hotspot mutations in signaling pathway activity. 
(A) In BRCA, tumor samples with H1047 missense hotspot mutations in PIK3CA show 
higher AKT pT308 and pS473 levels than those with no mutations in PIK3CA. (B) In COAD, 
tumor samples with E542 missense hotspot mutations in PIK3CA show higher AKT pT308 
and pS473 levels than those with no mutations in PIK3CA. * indicates p<0.05 and ** 
indicates p<0.001 between samples with specified hotspot mutations and samples with non-
hotspot mutations in examined gene; # indicates p<0.05 and ## indicates p<0.001 between 
samples with specified hotspot mutations and samples without mutations in examined gene. 
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responsiveness using data from the CCLE [71]. We divided cancer cell-line samples 
into different groups, depending on whether they contain specific hotspot, non-
hotspot, or no mutations in investigated gene candidates. Only mutations occurring 
at least twice were included in the comparison. Mann-Whitney U tests were 
performed to measure the difference between samples with individual hotspot 
mutations and samples with non-hotspot mutations, as well as between samples 
with individual hotspot mutations and samples without mutation [96]. Among 702 
hotspot mutations, we found 35 hotspot mutations lead to significantly altered drug 
sensitivities (Table S3.5). 
         We first illustrated the effect of individual hotspot mutations in BRAF, KRAS 
and NRAS on the sensitivity of cancer cells treated by MEK inhibitors (PD-0325901 
and AZD6244). As expected, cells with BRAF V600E mutations demonstrated 
significantly higher sensitivity to MEK inhibitors than those without BRAF mutations 
(data not shown). We also divided cells depending on their mutational status in 
NRAS. Specifically, we found that cells with NRAS Q61 hotspot mutations 
demonstrated significantly higher sensitivity to MEK inhibitors than those with non-
hotspot mutations and those without mutations in NRAS (Figure 3.8A). We further 
divided cells depending on their mutational status in KRAS and found only cells with 
KRAS G12 hotspot mutations demonstrated significantly higher sensitivity to MEK 
inhibitors than those with non-hotspot mutations and those without mutations in 
KRAS (Figure 3.8A). 
         It has been reported that TP53 mutations make cancer cells resistant to MDM2 
inhibitor (Nutlin-3) [104]. We specifically investigated the effect of different hotspot  
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Figure 3.8 Functional implications of hotspot mutations in drug sensitivity. (A) Cancer 
cells with NRAS Q61 or KRAS G12 missense hotspot mutations exhibit higher sensitivity to 
MEK inhibitors (PD-0325901 and AZD6244) than those with non-hotspot mutations or 
without any mutations in NRAS or KRAS. (B) Cancer cells with MAP3K4 A1199 deletion 
	  78	  
hotspot mutations exhibit lower sensitivity to different EGFR inhibitors (Erlotinib, Lapatinib, 
TKI258 and AZD0530) than those with non-hotspot mutations or without any mutations in 
MAP3K4. * indicates p<0.05 between samples with specified hotspot mutations and 
samples with non-hotspot mutations in examined gene; # indicates p<0.05 between samples 
with specified hotspot mutations and samples without mutations in examined gene. 
 
mutations and non-hotspot mutations of TP53. Surprisingly, we found cancer cells 
with four TP53 hotspot mutations (R175, R213, R248 and R273) showed 
significantly lower sensitivity to Nutlin-3 compared to cells without TP53 mutations 
(Figure S3.5 upper panel). Previous study has also suggested that HSP90 inhibitor 
(17-AAG) exhibits different effects on TP53 wild-type and mutant cells [105], we 
specifically measured the effect on cells with different TP53 mutations and found 
that only cells with two nonsense hotspot mutations (R213 and R342) are resistant 
to 17-AAG (Figure S3.5 lower panel) compared to cells without TP53 mutations, all 
the other missense hotspot mutations do not show significant effects.  
          Epidermal growth factor (EGF) is one of the high affinity ligands of EGFR. The 
EGF/EGFR system induces cell growth, differentiation, migration, adhesion and cell 
survival through various interacting signaling pathways such as the MAPK pathway 
[106], in which MAP3K4 is an important component [107]. Clinically, EGFR inhibitors 
such as Erlotinib were used to repress EGFR signaling activations and suppress 
tumor cell growth. However, we found that cancer cell-lines with MAP3K4 A1199 
deletion hotspot mutations were more resistant to all four examined EGFR inhibitors 
(Erlotinib, Lapatinib, TKI258 and AZD0530) in comparison to cancer cell-lines 
without MAP3K4 mutations (Figure 3.8B). These EGFR hotspot mutant cell-lines are 
also more resistant to three inhibitors (Erlotinib, Lapatinib and TKI258) in 
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comparison to cell-lines containing non-hotspot mutations in MAP3K4 (Figure 3.8B), 
suggesting the unique function of MAP3K4 A1199 deletion in disrupting the MAPK 
pathway function and its potential biomarker utility.  
         It has been well known that KRAS occupies a central role in multiple RTK 
signaling pathways, such as the IGF1-R and MET signaling pathway [108]. As 
expected, we measured the response of cancer cells with KRAS mutations and 
without KRAS mutations to IGF1-R inhibitor (AEW541) and c-MET inhibitors 
(PF2341066 and PHA-665752) and observed that cancer cells with KRAS mutations 
are resistant to IGF1-R inhibitor and c-MET inhibitors compared to cancer cell 
without KRAS mutation (data not shown). To specifically investigate the effect of 
individual KRAS mutations, we grouped the cancer cells by KRAS hotspot 
mutations, and found they were functionally diverse. As shown in Figure S3.6, KRAS 
G13 demonstrated the ability of making cells resistant to IGF1-R compared to cells 
with non-hotspot mutations and cells without KRAS mutations, KRAS G12 and 
KRAS Q61 showed minor resistant effect. KRAS G12 and G13 made cells resistant 
to c-MET inhibitors compared to cells with non-hotspot mutations and cells without 
KRAS mutations, while KRAS Q61 does not have notable resistant effects. 
         These observations above support that hotspot mutations we identified may 
have distinct roles in mediating signaling pathways and are associated with different 
drug sensitivities. Therefore, it is critical to obtain accurate genomic information and 
interpret them in context-specific manner in order to achieve desirable outcomes in 
personalized cancer treatment. 
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3.2.7 Tumor type-specific hotspot mutations 
        TCGA pan-cancer data enabled us to investigate the diverse function of a 
cancer gene in different tumor types. For example, TP53 was found to be important 
in most tumor types [109], and APC was important mostly in rectal (READ) and 
colon adenocarcinoma (COAD) [110]. However, related studies have thus focused 
on characterizing genes and it is largely unclear whether individual mutations 
demonstrate functionality that is specific to different tumor types. We performed an 
analysis to assess whether a hotspot mutation in our set is highly prevalent in 
specific tumor types. Among all the 702 hotspots, we found that 68 were highly 
prevalent in one tumor type, 11 in two tumor types, 2 (KRAS G12 and PIK3CA 
E542) in three tumor types, and 1 (KRAS G13) in four tumor types (Figure S3.7 and 
Table S3.6). Among these, 34 hotspot mutations such as CD209 R129 missense 
(4.0%) in bladder cancer, MAGI1 Q421 insertion (0.8%) and NR1H2 Q175 insertion 
(1.8%) in breast cancer were not well investigated based on previous studies and 
are potentially novel targets.  
         Of the 21 hotspot mutations detected in TP53 (Figure 3.9), 2 were found to be 
prevalent in multiple cancer types (R248 in bladder urothelial carcinoma (BLCA), 
BRCA and OV, R273 in lower grade glioma (LGG), BRCA and OV), and 9 (G108, 
R158, R175, I195, R213, Y220, R249, R282, E285) in one tumor type, confirming 
the functional diversity of TP53 hotspot mutations in different cancer types (Figure 
3.9). Our results indicated that the function of mutations in a gene may be highly 
heterogeneous in different tumor types. In addition, most hotspots appeared to be 
highly homogeneous, containing one subtype of mutation at any given amino acid  
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Figure 3.9 Prevalence of TP53 hotspot mutations in different TCGA cancer types. The 
hotspot mutations of TP53 are differentially prevalent in different tumor types, indicating their 
differential functions. 
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position. 
       Among various tumor types, COAD&READ had the highest number (24) of 
tumor type-enriched hotspot mutations (15 in APC, 3 in KRAS, 2 in FBXW7, and 1 in 
TP53, SMAD4, NRAS, and ERBB3 respectively), which again suggested a high 
degree of genetic complexity in colorectal cancer. We did not identify any tumor 
type-specific hotspot mutations in kidney renal papillary cell carcinoma (KIRP), 
which suggests that the development of KIRP may not involve a unique pathway and 
so may be generally similar to that of other tumor types (Figure S3.8).  
        We further identified 30 hotspot mutations that were exclusively detected in 
only one tumor type (Table 3.1). Included were DNMT3A R882 and NPM1 W288, 
which occur in 14.9% and 25.6% of acute myeloid leukemia (LAML) patients, 
respectively and have been shown important in LAML oncogenesis [111]. Besides 
these expected hotspots, we found some potentially novel hotspots. For example, 
we found an in-frame insertion hotspot mutation, NR1H2 Q175 in 1.8% of BRCA 
patients, further investigation using BRCA mRNA expression data showed that 
NR1H2 Q175 insertion is associated with reduced mRNA expression of NR1H2, 
comparing to NR1H2 non-hotspot mutations (Mann-Whitney U test, p=2.60e-2, 
Figure 3.10A). Although having been reported to regulate cholesterol homeostasis 
and tumorigenesis of liver cancer [112], the role of NR1H2 Q175 insertion in BRCA 
has not been well characterized. In addition, GATA3 P409, a frame-shift insertion 
hotspot mutation was detected in 1.6% of BRCA patients. BRCA samples with 
GATA3 P409 insertions had higher expressions of GATA3 compared to samples  
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Table 3.1 Hotspot mutations exclusively detected in only one tumor type in TCGA pan-
cancer data 
 
Tumor_Type Gene aa_Pos Frequency adj_Pvalue 
BLCA RXRA S427 5.00% 4.26E-08 
BRCA GATA3 P409 1.60% 5.48E-09 
BRCA GOLGA6L2 E537 0.90% 1.27E-04 
BRCA MAGI1 Q421 0.80% 4.95E-04 
COAD&READ APC R876 5.30% 4.01E-14 
KIRC NEFH P655 0.70% 2.16E-03 
LAML FLT3 D835 8.20% 1.94E-21 
LAML NPM1 W288 25.60% 1.58E-69 
LAML DNMT3A R882 14.90% 4.24E-38 
SKCM AGAP10 M293 2.80% 1.62E-08 
SKCM C15orf23 S24 2.80% 1.62E-08 
SKCM PCDHGA1 R293 2.00% 3.48E-06 
SKCM TRRAP S722 1.60% 4.83E-05 
STAD BMPR2 N583 2.00% 1.49E-04 
STAD CCDC43 R216 2.00% 1.49E-04 
STAD ESRP1 N512 3.30% 3.25E-07 
STAD FAM18A F140 2.00% 1.49E-04 
STAD GTF2I N440 2.00% 1.49E-04 
STAD STAMBPL1 K405 2.00% 1.49E-04 
STAD ZNF365 K399 2.00% 1.49E-04 
STAD CNBD1 L396 2.00% 4.68E-04 
STAD DOCK3 P1852 6.60% 2.47E-13 
STAD PGM5 I98 10.50% 5.36E-22 
STAD SLC3A2 K331 2.60% 3.15E-05 
STAD UBR5 E2121 5.30% 1.72E-10 
UCEC FGFR2 S252 3.60% 6.31E-11 
UCEC MAX H28 1.60% 4.55E-05 
UCEC BCOR N1459 3.20% 7.14E-09 
UCEC PIK3CA R93 2.40% 1.25E-06 
 
Note: Frequency was calculated by dividing number of mutations over number of samples in 
specific tumor type; adjusted p-value was computed based on Fisher’s exact test followed by 
FDR correction. 
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Figure 3.10 Prevalence of hotspot mutations in different TCGA cancer types and their 
functional implications. (A) In BRCA, samples with NR1H2 Q175 in-frame insertion 
hotspot mutations have significantly lower NR1H2 expression compared to samples with 
NR1H2 non-hotspot mutations. (B) In BRCA, sample with GATA3 P409 insertion hotspot 
mutations have obviously higher GATA3 compared to samples without GATA3 mutation. * 
indicates p<0.05 between samples with specified hotspot mutations and samples with non-
hotspot mutations in examined gene; # indicates p<0.05 between samples with specified 
hotspot mutations and samples without mutations in examined gene. 
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without GATA3 mutations based on both the BRCA mRNA expression (Mann-
Whitney U test, p=2.03e-2) and RRPA data (Mann-Whitney U test, p=5.94e-2, 
Figure 3.10B). Because GATA3 has been proposed as a prognostic biomarker in 
breast cancer [113], the high frequency of GATA3 P409 and elevated GATA3 
expression in BRCA make them potential useful therapeutic targets in clinics. 
3.2.8 Conservation and protein-domain characteristics of the hotspot 
mutations 
         In general, functional and structural important mutations are expected to locate 
in highly evolutionally conserved region and domain in the protein. To evaluate our 
hotspot mutation, we used the RS scores computed by GERP++ [97], to measure 
the evolutionary constraints across different chromosomal sites (Methods). We 
compared the RS score difference between the sites that belong to hotspot 
mutations and those belong to non-hotspot mutations. The RS scores of 702 hotspot 
mutations were significantly higher than those of non-hotspot mutations (Figure 
3.11A), suggesting the sites that harbor hotspot mutations were more conserved 
than those do not. In addition, we also examined the relative location of mutations on 
the protein. The non-hotspot mutations were evenly distributed across different 
domains of the protein (lower panel), while the hotspot mutations showed clustering 
in the middle and the terminals (Figure 3.11B, upper panel), suggesting the 
functional preference of mutations in different protein domains. 
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Figure 3.11 Comparing the conservation and proteomic domain localization of the 
hotspot and the non-hotspot mutations. (A) Comparison of GERP score between the 
hotspot and non-hotspot mutations. (B) Investigation of the proteomic domain location of the 
hotspot (upper) and non-hotspot (lower) mutations. 
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3.3 Discussion 
         We nominated 702 hotspot mutations in 549 genes from the COSMIC 
database, among which 53 were associated with statistically significant functional 
evidences in currently available TCGA and CCLE data (Table S3.5). The rest of the 
hotspot mutations could not be associated with additional functional evidence, which 
may due to sparseness in the data and limitations in the current knowledge bases. 
For example, only 187 antibodies were measured on the RPPAs, the sample size 
was relatively small and some observed patterns might change as the sample size 
increases in the future. Nonetheless, our study revealed differential biological 
consequences and pharmacogenomics utilities of mutations under different disease 
contexts and highlighted the significance of allocating the specific function of 
individual mutations using functional genomics and pharmacogenomics data. These 
aspects have not been systematically explored in previous studies. Besides 
investigating previous known hotspot mutations in different contexts, we also 
nominated a set of novel hotpot mutations such as those in MAP3K4, NR1H2 and 
GATA3 with corresponding functional associations, which represent good 
candidates for developing predictive biomarkers and drug targets. 
        Investigating the mutational signatures in different cancer types has been a 
useful tool for understanding the underlying biological processes of cancer 
development. Alexandrov et al. [114] dissected all the mutations in TCGA into 21 
distinct mutational signatures with diverse sequence context enrichments and 
associated them with different phenotypes such as age of the patient at cancer 
diagnosis, known mutagenic exposures or defects in DNA maintenance. Kandoth et 
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al. [115] investigated 12 cancer types in TCGA and reported that mutations were 
enriched in C/G transitions such as C->T and C/G transversions such as C->A in 
different cancer types using all the mutation data. In our study, we focused on 
predicted hotspot mutations and illustrated the mutational signatures that hotspot 
mutations represented. We found that hotspot mutations were enriched in 
NoCpG_CGts and NoCpG_CGtv sequence context in 10 tumor types and some 
sequence contexts such as ATtv in bladder cancer. In addition, we elucidated that 
insertion mutations were highly enriched in breast cancer and deletion mutations 
were enriched in colorectal cancer, which was a novel finding in our study. 
        Another novel contribution of our current investigation was to highlight the 
criticalness of distinguishing the biological roles of individual hotspot mutations 
within one cancer gene under different disease contexts. Different hotspot mutations 
within one gene can exhibit diverse functional indications. For example, only PIK3CA 
H1047 but not any other hotspot mutations enhances the AKT pathway activity in 
BRCA, while only PIK3CA E542 enhances the AKT pathway activity in COAD. 
Previous studies observed that PIK3CA H1047R and E545K both result in a 
constitutively active enzyme with oncogenic capacity but the effect of H1047R is 
much stronger than E545K [116, 117]. We may not have seen obvious E545K 
enhancement of the AKT pathway activity because: 1) insufficient samples carrying 
the PIK3CA E545K mutation in our current analysis; and 2) highly sparse expression 
of phospho-AKT in samples without PIK3CA mutation. Similarly, one hotspot 
mutation can represent different functional relevance in different cancer types. For 
example, with TP53, R248 and R273 significantly increase its RNA and protein 
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expression in BRCA and OV but not in READ. In addition, different TP53 hotspot 
mutations were prevalent in various cancer types, and 30 hotspot mutations 
exclusively occur in only one cancer type. Although it was interesting to observe the 
differential functional correlation of hotspot mutations in different disease contexts, to 
further improve the convincingness of the conclusions achieved in our study, power 
analysis would be an ideal way to evaluate the reliability of functional correlation 
analysis, especially when measuring the differential functional impact of an identical 
hotspot mutation across different cancer types. 
         Along the line of identifying hotspot mutations, it was commonly assumed that 
mutations close to each other are expected to exhibit similar functions and grouping 
nearby mutations as a hotspot would improve the power of identifying driver 
mutations. One important observation of our study was we found that even hotspot 
mutations close to each other could have distinct biological implications in the same 
cancer type. For example, PIK3CA E542 was significantly associated with 
enhancement of phospho-AKT activities in COAD, while E545 did not; cell-lines with 
KRAS G13 were resistant to IGF-1R inhibitor (AEW541), while those with G12 did 
not (data not shown). Nearby hotspot mutations demonstrated distinct functions 
under different disease context. Simply collapsing mutations based on proximity and 
assuming that nearby mutations have the same functions may result in errors in 
functional prediction. 
         Although available functional genomic data prohibited us from systematically 
characterizing every hotspot mutation we predicted, our integrative assessment 
based on mRNA expression, protein activity, drug sensitivity, and tumor specificity 
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data in TCGA and CCLE, indicated potential utility of each of our predicted hotspot 
mutations. Such functional characterization can be unequivocally improved in the 
future by using systematic pathway-aware algorithms such as DriverNet [118] and 
PARADIGM-SHIFT [119], and by integrating additional functional genomic datasets 
such as Genomics of Drug Sensitivity in Cancer (GDSC) [72]. In addition, further 
dissecting the mutation data into different groups would be helpful to distinguish 
distinct mutation profiles and precisely investigate the specific function of hotspot 
mutations in different cancer subtypes. For example, different cancer subtype 
groups (such as MSI and non-MSI in colorectal cancer, ER+, HER2+ and TNBC in 
breast cancer) or considering the co-founding factors across the population (such as 
age, sex, ethics). When evaluate the enrichment of hotspot mutations in a specific 
cancer type, it is also valuable to dive into cancer subtypes and investigate whether 
any hotspot mutations only occur in specific cancer subtype (for example, TNBC in 
breast cancer). Importantly, our results demonstrated a high degree of functional 
heterogeneity at the mutational level, which has not been sufficiently apprehended 
or investigated in current research and clinical practice. Despite all the caveats, the 
hotspot mutations we identified provide a step forward in cataloging hotspot driver 
mutations in different cancer types and biological contexts, which is critical for 
realizing the promise of personalized cancer medicine. 
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CHAPTER 4 
 
Conclusions and future directions 
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4.1 Conclusions 
         In the dissertation study, I focused on investigating the possibility of applying -
omics data to enhance the capability of precision medicine. To achieve this essential 
goal, we performed the studies through two aspects: 1) Illustrated the potential 
ambiguities in variant annotations, and developed TransVar to help resolve such 
ambiguities and greatly increase the accuracy of applying variant annotations in 
different research and clinical fields; 2) Proposed a population-based statistical 
model to identify hotspot mutations in amino acid resolution, and elucidated their 
mutational signatures and diverse biological utilities across different cancer types. 
        We developed TransVar, which is a comprehensive variant annotator that 
performs multi-level variant annotation such as forward annotation from genomic to 
RNA and to protein level, and reverse annotation from protein to RNA and to 
genomic level. We implemented the command line tool and make TransVar highly 
flexible of handling different formats of data input. Essentially, TransVar supports not 
only the standard variant format that was recommended by HGVS nomenclature, but 
also formats that were frequently used by researchers. 
        We investigated the various areas that the reverse and equivalence annotation 
function of TransVar could potentially contribute to: 1) experimental validation 
design; 2) clinical pharmacogenomics; and 3) hotspot mutation prediction. With the 
comprehensive functions of TransVar, the ambiguities that were encountered 
frequently in biological investigation and clinical treatment decision-making could be 
largely removed. In addition, our investigation revealed the frequent annotation 
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inconsistencies in current databases. We used the mutation data in TCGA and 
COSMIC to show large inconsistencies between the annotation practices in these 
two mutation databases. We used the COSMIC data to compare the forward 
annotation consistencies that were achieved by TransVar and other existing 
annotations, and showed that TransVar could provide the most comprehensive 
information available to allow the users to fully capture the potential protein variants 
that were annotated from a specific genomic variant. Our study also tried to illustrate 
the ambiguities of reverse annotation among different transcript databases and 
different mutation types. With both forward and reverse annotation that was enabled 
in TransVar, we can reveal hidden inconsistency and significantly improve the 
precision of translational and clinical genomics. The source code and detailed 
instructions for TransVar are available at https://bitbucket.org/wanding/transvar and 
a web interface is at http://www.transvar.net. 
        By investigating mutation data of 17 different tumor types in COSMIC, we 
observed a large discordancy of mutation rates across different mutation subtypes 
and tumor types. By respecting those mutation variations, we developed a 
population-based statistical model to nominate 702 hotspot mutations in 549 cancer 
genes using COSMIC data in a gene, tumor type, mutation subtype and sequence 
context specific manner. We illustrated the common and distinct mutational 
signatures of hotspot mutations across different tumor types, we found a high 
enrichment of Non-CpG island C/G transition and transversion in 10 tumor types, 
insertion hotspots are highly prevalent in Breast cancer, and deletion hotspots are 
enriched in colon cancer. We also employed multi-dimensional functional evidence 
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(RNA sequencing, reverse phase protein array and pharmacogenomics data) to 
demonstrate the diverse functional relevance of hotspot mutations in different 
biological and disease contexts and nominate a set of novel hotspot mutations such 
as MAP3K4 A1199 deletion, NR1H2 R175 insertion, and GATA3 P409 insertion with 
different functional associations. Our results will promote our understanding of the 
process of genomic positive selection by investigating the mutational signatures on 
hotspot mutations and facilitate ongoing efforts in cancer target discovery and 
development [120]. The source code used for our analysis is available at 
https://sourceforge.net/projects/hotdriver/.  
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4.2 Future directions 
        With the quick expansion of high dimensional data in the past few years, more 
and more attention has been paid to exploring the utility of -omics data in clinical 
applications. These greatly improved our capability of performing clinical 
management and developing novel drugs, and therefore allowed us to get close to 
the goal of personalized medicine. 
        Through the current functions enabled by TransVar, we are able to perform 
cross-level variant annotation in genomic, RNA and protein levels. The functions of 
TransVar could help the researchers and clinicians resolve some ambiguities such 
as experimental validation design, clinical pharmacogenomics and hotspot mutation 
prediction. In the future, we will try to further expand the potential applications of 
TransVar in other biological contexts: 1) annotate the functional impact of a variant 
such as in any specific protein domain locations, epigenetic regulatory domains, etc; 
2) explore the application of TransVar in shRNA design to make sure that the 
shRNA targeted region globally exists in all transcript isoforms of a specific gene; 3) 
investigate the effects of genomic editing CRISPR-Cas9 on the protein level and the 
consequence on the RNA expression. 
         We developed a population-based statistical model to nominate 702 hotspot 
mutations in 549 cancer genes using COSMIC data in a gene, tumor type, mutation 
subtype and sequence context specific manner. We employed multi-dimensional 
functional evidence to demonstrate the diverse functional relevance of hotspot 
mutations in different contexts and nominate a set of novel hotspot mutations with 
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functional indications. In the future, we can apply the statistical model to different in-
house or publically available mutation cohorts to identify hotspot mutations. 
Specifically, it would be interesting to identify hotspot mutations in different public 
datasets such as ICGC and TCGA, and investigate whether the hotspot mutations 
nominated are different and if there are any specific hotspot mutations occur in 
specific dataset. Beside, our current model focused on identify hotspot mutations of 
single amino acids, we will further investigate whether grouping close-by mutations 
will enhance the power of identifying functional mutations. In terms of functional 
indication of hotspot mutations, we will try to 1) evaluate the pathway activities and 
systematically evaluate the effect of hotspot mutations on different pathway 
activities; and 2) utilize power analysis to evaluate the confidence of our statistical 
analysis.  
         With the advance of genomics and pharcogenomics research, people 
gradually realize that that clinical drug response is partially determined by the 
genomic alterations and gene expression changes in each particular patient. In the 
future, we will be interested in utilizing comprehensive -omics data to help predict 
specific drug response and looking for promising biomarker signatures that could 
help inform the clinical treatment decision making given a patient’s -omic profiles. 
Through this type of study, we will be able to 1) implement a statistical model that is 
suitable to identify the drug response in a drug-based manner; and 2) discover 
biomarkers that can be used to stratify the patient groups when decide which drug 
should be choose to treat the patient. These observations could greatly help the 
capability of future patient diagnosis and clinical treatment. In addition, given 
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different molecular data types for each drug, we tend to investigate which we could 
achieve the best drug response prediction, such as using a specific data type or a 
combination of different data types. Furthermore, we tend to evaluate whether 
additional knowledge can be helpful to further improve the drug response prediction, 
such as accurate mutation annotation, driver/hotspot mutation information and 
pathway network knowledge. This will be a good continuation of our efforts in the 
current thesis and will illustrate whether my thesis can be further helpful in different 
biological and therapeutic contexts. 
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Appendix 
 
Supplemental Figures: 
 
 
 
Figure S2.1 Illustration of reporting ambiguity for a 3 bp insertion CTG at (A) 
genomic/mRNA levels and (B) protein level. Note that positional justifications on the 
protein level are agnostic of the base sequence on the DNA level and may result in variable 
amount of shifts. 
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Figure S3.1 The percentage of different mutational subtypes across all defined 
hotspot mutations. On each hotspot locus, only the mutational subtype that occupies the 
highest number of mutations was counted. 
 
 
 
 
Figure S3.2 The significance of overlap (y-axis, calculated using Fisher exact test) 
between hotspot-mutation-containing-genes and previously known cancer genes at 
various adjusted p value cutoffs (x-axis). 
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Figure S3.3 Relationship between the number of hotspot mutations and the total 
number of mutations (mutation burden) in each tumor type. 
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Figure S3.4 Functional implications of hotspot mutations in RNA and protein 
expression. In OV, tumor samples with missense hotspot mutations (I195, Y220, R248 and 
R273) in TP53 show higher TP53 RNA and protein expression than those with non-hotspot 
mutations and without TP53 mutations. * indicates p<0.05 and ** indicates p<0.001 between 
samples with specified hotspot mutations and samples with non-hotspot mutations in 
examined gene; # indicates p<0.05 and ## indicates p<0.001 between samples with 
specified hotspot mutations and samples without mutations in examined gene. 
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Figure S3.5 Functional implications of hotspot mutations in drug sensitivity. Cancer 
cells with TP53 R175, R213, R248 and R273 hotspot mutations show resistant to MDM2 
inhibitor (Nutlin-3) compared to those without TP53 mutations, while cancer cells with TP53 
R213 and R342 nonsense mutations are resistant to HSP90 inhibitor (17-AAG) compared to 
those without TP53 mutations. * indicates p<0.05 between samples with specified hotspot 
mutations and samples with non-hotspot mutations in examined gene; # indicates p<0.05 
between samples with specified hotspot mutations and samples without mutations in 
examined gene. 
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Figure S3.6 Functional implications of hotspot mutations in drug sensitivity. 
Cancer cells with KRAS G13 missense hotspot mutations show resistant to IGF-1R inhibitor 
(AEW541) compared to those with non-hotspot mutations and without KRAS mutations, 
while cancer cells with KRAS G12 and G13 missense mutations are resistant to c-MET 
inhibitor (PF2341066 and PHA-665752) compared to those with non-hotspot mutations and 
without TP53 mutations. * indicates p<0.05 between samples with specified hotspot 
mutations and samples with non-hotspot mutations in examined gene; # indicates p<0.05 
between samples with specified hotspot mutations and samples without mutations in 
examined gene. 
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Figure S3.7 Prevalence of hotspot mutations in different TCGA cancer types. 82 
hotspot mutations were highly prevalent in one or more cancer types. Most are highly 
prevalent in only one tumor type, while a few were in two or more tumor types. 
 
 
 
Figure S3.8 Numbers of highly prevalent hotspot mutations in different tumor types 
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Supplemental Tables: 
 
 
 
Table S2.1 Comparing the annotation consistency of different mutation types using 
TransVar, VEP, ANNOVAR, snpEff and Oncotator. We annotated 964,162 unique SNSs, 
3,715 MNSs, 11,761 INSs, 24,595 DELs and 166 BLSs in catalogue of somatic mutations in 
cancer (COSMIC) and counted if the resulting annotations (gene names, amino acid 
positions and alterations) match the corresponding protein identifiers in COSMIC. 
 
 
 TransVar VEP ANNOVAR snpEff Oncotator 
SNS 96.1% 92.9% 91.6% 91.9% 91.8% 
MNS 96.8% 92.6% NA1 77.5% 92.6% 
INS2 80.6% 75.8% 32.4% 34.6% 38.4% 
DEL2 87.8% 77.1% 48.7% NA1 55.6% 
BLS 81.9% 75.6% NA1 70.5% 35.5% 
 
 
1 Protein level annotations not available. 2 TransVar reports both 5’-aligned and 3’-aligned 
results; VEP only reports the 3’-aligned protein variants with or without --shift_hgvs option, 
while ANNOVAR, snpEff and Oncotator report only 5’-aligned results. 
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Table S3.1 Number of samples in 17 tumor types in COSMIC v71 
 
 
Tumor Type COSMIC samples * WGS&WEX ^ Exclude Hyper-mutator # 
Bladder 3872 364 358 
Bone 704 81 79 
Brain 8457 1366 1354 
Breast 4994 1152 1140 
Colon 29413 694 684 
Endometrium 2293 271 260 
Head&Neck 3036 710 699 
Kidney 3616 879 867 
Liver 2448 900 890 
Lung 10520 969 951 
Myeloid 52500 1344 1336 
Ovarian 3378 647 640 
Pancreas 5561 800 789 
Prostate 953 508 501 
Skin 9072 655 650 
Stomach 3615 621 613 
Thyroid 13967 444 439 
 
 
* Number of samples that were collected by COSMIC v71; ^ Number of samples that were 
subjected to either whole genome or whole exome sequencing; # Number of samples after 
excluding samples that were shown to be hyper-mutated. 
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Table S3.2 20 mutation subtypes that were included in the statistical modeling of 
hotspot mutation definition 
 
 
Mutation_subtype 
Missense A/T transition 
Missense A/T transversion 
Missense non-CpG C/G transition 
Missense non-CpG C/G transversion 
Missense CpG C/G transition 
Missense CpG C/G transversion 
Nonsense A/T transition 
Nonsense A/T transversion 
Nonsense non-CpG C/G transition 
Nonsense non-CpG C/G transversion 
Nonsense CpG C/G transition 
Nonsense CpG C/G transversion 
Silent A/T transition 
Silent A/T transversion 
Silent non-CpG C/G transition 
Silent non-CpG C/G transversion 
Silent CpG C/G transition 
Silent CpG C/G transversion 
Insertion 
Deletion 
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Table S3.3 Number of samples available in different TCGA cancer types. 
 
Abbreviation Tumor_Type Mutation RNA RPPA Mut_RNA Mut_RPPA 
BRCA Breast Invasive Carcinoma 772 817 748 752 637 
KIRC Kidney Renal Clear Cell Carcinoma 417 470 455 391 386 
THCA Thyroid Carcinoma 323 426 NA 303 NA 
OV Ovarian Serous Cystadenocarcinoma 316 263 413 163 210 
HNSC Head & Neck Squamous Cell Carcinoma 306 303 213 299 208 
GBM Glioblastoma Multiforme 291 161 216 150 146 
SKCM Skin Cutaneous Melanoma 253 NA NA NA NA 
UCEC Uterine Corpus Endometrioid Carcinoma 248 333 404 239 203 
LUAD Lung Adenocarcinoma 230 353 238 169 135 
COAD-READ Colon & Rectum Adenocarcinoma 224 263 466 217 157 
LAML Acute Myeloid Leukemia 194 173 NA 169 NA 
LUSC Lung Squamous Cell Carcinoma 178 220 196 177 112 
LGG Brain Lower Grade Glioma 170 205 NA 166 NA 
STAD Stomach Adenocarcinoma 151 58 NA 58 NA 
KIRP Kidney Renal Papillary Cell Carcinoma 100 78 NA 77 NA 
BLCA Bladder Urothelial Carcinoma 99 96 128 95 92 
PRAD Prostate Adenocarcinoma 83 142 NA 72 NA 
CESC Cervical Squamous Cell Carcinoma 39 97 NA 38 NA 
PAAD Pancreatic Adenocarcinoma 34 41 NA 19 NA 
 
Note: The number of samples with somatic mutation data, RNA expression data, RPPA 
data, or both data types (Mut_RNA and Mut_RPPA) in each TCGA cancer type. The data 
was last updated in November 2014. 
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Table S3.4 2×2 table of calculating the prevalence of target mutation B in samples A 
 
Number of A samples  
with B mutations 
Number of A samples 
without B mutations 
Number of non-A samples 
with B mutations 
Number of non-A samples 
without B mutations 
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Table S3.5 List of the predicted hotspot mutations in different tumor types based on 
COSMIC version 71 
 
 
Gene aaPos Tumor_type 
ATXN2L R382 Bladder 
CD209 R129 Bladder 
CD36 V103 Bladder 
COQ10A L35 Bladder 
COQ10A L50 Bladder 
COQ10A L67 Bladder 
ENSG00000196306 D252 Bladder 
FGFR3 R248 Bladder 
FGFR3 S249 Bladder 
FGFRL1 H485 Bladder 
FRG2C A277 Bladder 
HRAS G12 Bladder 
HRAS Q61 Bladder 
KDM3A R157 Bladder 
KRAS G12 Bladder 
KRTAP10-1 D159 Bladder 
MUC4 D2389 Bladder 
MUC6 Y1920 Bladder 
NEFH P655 Bladder 
NOTCH2 A21 Bladder 
PCDH11X A89 Bladder 
PIK3CA E542 Bladder 
PIK3CA E545 Bladder 
PLXNA1 G36 Bladder 
RALGAPA1 Q15 Bladder 
RP5-1086D14.3 F374 Bladder 
RXRA S427 Bladder 
SENP6 Y599 Bladder 
TCF7L2 A87 Bladder 
TMPRSS13 A77 Bladder 
TMPRSS13 Q78 Bladder 
TNKS1BP1 A944 Bladder 
TP53 R248 Bladder 
TP53 E285 Bladder 
ZBTB17 A144 Bladder 
ZBTB17 A207 Bladder 
ZNF233 L662 Bladder 
ZNF83 G267 Bladder 
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ZNF83 E293 Bladder 
IDH1 R132 Bone 
OBSCN L1039 Bone 
TTN R139 Bone 
ACTR3B V136 Brain 
AKR1C2 L261 Brain 
AKR1C2 Y5 Brain 
ANK2 L1097 Brain 
ANK2 T3651 Brain 
ASPM K3446 Brain 
BRAF V600 Brain 
CDC42BPA P422 Brain 
CDKL5 S603 Brain 
CHEK2 Y390 Brain 
CHEK2 A392 Brain 
CHEK2 R519 Brain 
CHEK2 P522 Brain 
CHEK2 P536 Brain 
COBL P23 Brain 
CTNNB1 S33 Brain 
EGFR A289 Brain 
EGFR G598 Brain 
EPHA5 V475 Brain 
ERC2 R20 Brain 
FGFR1 N546 Brain 
FGFR1 K656 Brain 
FKBP9 R107 Brain 
FKBP9 I274 Brain 
FKBP9 I42 Brain 
H3F3A K28 Brain 
HIF1A K213 Brain 
HIF1A D238 Brain 
IDH1 R132 Brain 
IDH2 R172 Brain 
IRS4 A640 Brain 
ITGAV R775 Brain 
KLF4 K409 Brain 
KPNA2 F17 Brain 
KTN1 E687 Brain 
MAP3K6 N614 Brain 
MAP3K6 N622 Brain 
MAX R60 Brain 
NBPF10 K3445 Brain 
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NBPF10 E3455 Brain 
NCOA6 Q269 Brain 
PARD3B G308 Brain 
PARG A584 Brain 
PIK3C2B R41 Brain 
PIK3CA H1047 Brain 
PIK3CA E545 Brain 
POTEM V308 Brain 
RGPD8 P1760 Brain 
RPSAP58 Q111 Brain 
SMAD4 L23 Brain 
SOX11 L326 Brain 
SYNPO2 R340 Brain 
TBK1 E109 Brain 
TBK1 T79 Brain 
THAP3 E160 Brain 
TP53 R158 Brain 
TP53 R175 Brain 
TP53 H179 Brain 
TP53 R196 Brain 
TP53 R213 Brain 
TP53 Y220 Brain 
TP53 G245 Brain 
TP53 R248 Brain 
TP53 R249 Brain 
TP53 R273 Brain 
UBBP4 L149 Brain 
UBBP4 R73 Brain 
WASH3P G374 Brain 
ZNF429 E395 Brain 
ZNF429 N426 Brain 
ZNF429 K528 Brain 
ZNF429 K556 Brain 
ZNF429 K568 Brain 
ZNF429 R672 Brain 
ZNF814 D404 Brain 
AKT1 E17 Breast 
BCL6B S244 Breast 
BTNL8 V21 Breast 
C10orf140 E428 Breast 
DDX11 E310 Breast 
FLJ42177 V295 Breast 
GOLGA6L2 E537 Breast 
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HSPD1 R24 Breast 
KCNN3 L66 Breast 
KRAS G12 Breast 
MAGI1 Q421 Breast 
MAP3K4 A1199 Breast 
NCOA3 Q1255 Breast 
NCOR2 Q510 Breast 
NR1H2 Q175 Breast 
PIK3CA H1047 Breast 
PIK3CA N345 Breast 
PIK3CA E542 Breast 
PIK3CA E545 Breast 
RBMX P106 Breast 
SF3B1 K700 Breast 
TBP Q76 Breast 
TP53 G108 Breast 
TP53 R175 Breast 
TP53 C176 Breast 
TP53 H193 Breast 
TP53 R196 Breast 
TP53 R213 Breast 
TP53 Y220 Breast 
TP53 R248 Breast 
TP53 R273 Breast 
USP36 K959 Breast 
AATK G703 Colon 
ABCA7 A2045 Colon 
ABCF1 K76 Colon 
ACTR5 F6 Colon 
ADAD2 G44 Colon 
ADAM22 P81 Colon 
ADAM29 T746 Colon 
ALDH2 L189 Colon 
ALOX12 P41 Colon 
ANKRD30A P818 Colon 
ANTXR2 A357 Colon 
ANXA2 C8 Colon 
APC R1114 Colon 
APC R1450 Colon 
APC R876 Colon 
ARHGAP5 V474 Colon 
ARHGEF33 S582 Colon 
ATM R337 Colon 
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ATR I774 Colon 
ATXN7 T781 Colon 
BAX E41 Colon 
BCAS4 E56 Colon 
BCL9L P1128 Colon 
BIRC6 K4503 Colon 
BMPR1A R486 Colon 
BMPR2 N583 Colon 
BRAF V600 Colon 
BRAT1 R644 Colon 
BRCA2 S1682 Colon 
C17orf82 L186 Colon 
C1orf106 R538 Colon 
C8orf55 L63 Colon 
C8orf80 N631 Colon 
CACNA1H D2133 Colon 
CASP5 R23 Colon 
CBWD6 L260 Colon 
CCDC43 R216 Colon 
CD3G K71 Colon 
CD8B L9 Colon 
CDC42BPA S344 Colon 
CDKN2D R30 Colon 
CEBPB A147 Colon 
CHEK2 S372 Colon 
CHEK2 K373 Colon 
CHML S514 Colon 
CLK4 R2 Colon 
CLOCK L123 Colon 
CSNK1D S97 Colon 
CSNK1E N172 Colon 
CYP21A2 L10 Colon 
D2HGDH R55 Colon 
DDHD1 G112 Colon 
DDX26B L120 Colon 
DDX4 P48 Colon 
DEFB126 P106 Colon 
DLC1 K237 Colon 
DLC1 R347 Colon 
DNAH3 S1608 Colon 
DNTTIP1 P13 Colon 
DOCK3 P1852 Colon 
DOT1L G1386 Colon 
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DSC2 K270 Colon 
DSG4 A601 Colon 
DSPP S879 Colon 
EBPL F172 Colon 
EEF1D D189 Colon 
ENSG00000269210 G98 Colon 
ERI1 L16 Colon 
ESRP1 N512 Colon 
ETHE1 A2 Colon 
ETNK2 P10 Colon 
FADS3 A18 Colon 
FAM18A F140 Colon 
FAM190A D515 Colon 
FAM190A E611 Colon 
FAM194B E135 Colon 
FAM194B E136 Colon 
FAM194B E138 Colon 
FAM194B Y139 Colon 
FBXW7 R465 Colon 
FEZ2 P50 Colon 
FGFR1 T141 Colon 
GLTPD2 D209 Colon 
GOT1L1 T415 Colon 
GPHB5 R53 Colon 
GPRIN2 G237 Colon 
GRID2IP A221 Colon 
GRIK2 N849 Colon 
GSG2 R82 Colon 
GSX1 L78 Colon 
GTPBP3 T66 Colon 
HAP1 K4 Colon 
HCLS1 P368 Colon 
HECW1 R1502 Colon 
HLA-DQA1 G79 Colon 
HSD17B1 G313 Colon 
HSPA12B C627 Colon 
IDH3A S8 Colon 
IFI27 A43 Colon 
IFITM3 P55 Colon 
IGF2R D1317 Colon 
IRF5 P183 Colon 
JPH4 A502 Colon 
KDM5A G1200 Colon 
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KIAA1024 S702 Colon 
KIF17 R13 Colon 
KIF25 W3 Colon 
KLF14 S112 Colon 
KLHL30 A213 Colon 
KNDC1 A432 Colon 
KNDC1 V806 Colon 
KRAS G12 Colon 
KRAS G13 Colon 
KRT4 G155 Colon 
KRTAP4-3 R26 Colon 
KRTAP4-3 Q31 Colon 
KRTAP9-1 C153 Colon 
KSR1 P291 Colon 
LATS2 A324 Colon 
LIG1 K152 Colon 
LMAN1 E305 Colon 
LRRIQ1 R329 Colon 
MAGEB2 R23 Colon 
MAML2 Q596 Colon 
MAPK9 K56 Colon 
MEGF11 A102 Colon 
MEGF11 A177 Colon 
MLL3 Y366 Colon 
MLL3 T3698 Colon 
MRE11A F237 Colon 
MSH3 K374 Colon 
MTX1 T63 Colon 
MUC2 T1541 Colon 
MUC2 T1542 Colon 
MUC4 T113 Colon 
MUC6 P1570 Colon 
MUC6 P1571 Colon 
MUC6 T1911 Colon 
MYOM1 R212 Colon 
NEFH E645 Colon 
NEFH A646 Colon 
NFATC3 K474 Colon 
NFKB2 P423 Colon 
NIN E1559 Colon 
NIPBL K603 Colon 
NOTCH3 P1521 Colon 
NRAS G12 Colon 
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NRAS Q61 Colon 
NTSR2 A54 Colon 
OBSCN A94 Colon 
OPRD1 C27 Colon 
OR5K4 I301 Colon 
OR6C76 K311 Colon 
ORAI1 P43 Colon 
PANX2 P505 Colon 
PANX2 L555 Colon 
PCDHA7 L352 Colon 
PCDHGC3 N689 Colon 
PCSK5 E562 Colon 
PDXDC1 A384 Colon 
PDXDC1 A407 Colon 
PHF2 P988 Colon 
PIK3CA H1047 Colon 
PIK3CA E542 Colon 
PIK3CA E545 Colon 
PIK3CA R88 Colon 
PKD1L2 N236 Colon 
PKDCC G17 Colon 
PLEC L1184 Colon 
PLEC A1976 Colon 
POLE V1394 Colon 
PPP2R3B P533 Colon 
PRRT4 R391 Colon 
PRSS36 S423 Colon 
PTPLA E64 Colon 
PTPRD R584 Colon 
PURB A107 Colon 
RAPGEF6 S640 Colon 
RASA2 E759 Colon 
RASSF5 L16 Colon 
RBBP8 K357 Colon 
RBP1 P18 Colon 
RHPN2 A353 Colon 
RIC8A P210 Colon 
RLIM S501 Colon 
RNF145 K23 Colon 
RNF145 N27 Colon 
SBK2 A298 Colon 
SCARF2 R727 Colon 
SCRIB P1450 Colon 
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SF1 E28 Colon 
SLAMF1 S277 Colon 
SLC39A3 V236 Colon 
SLC3A2 K331 Colon 
SMAD4 R361 Colon 
SNX13 L652 Colon 
SNX18 G204 Colon 
SOLH A840 Colon 
SP5 A75 Colon 
SPHK1 A34 Colon 
SRPR K170 Colon 
STAMBPL1 K405 Colon 
STARD3NL T130 Colon 
SVIL M1863 Colon 
SgK069 A298 Colon 
SgK223 G350 Colon 
SgK493 G160 Colon 
TAF1B N66 Colon 
TBC1D8B K118 Colon 
TCERG1 K957 Colon 
TCF15 T113 Colon 
TCF15 V114 Colon 
TEAD2 H295 Colon 
TFAM E148 Colon 
TMBIM4 Y174 Colon 
TMEM131 G44 Colon 
TMEM151B L332 Colon 
TMEM60 A78 Colon 
TMPRSS13 A77 Colon 
TMPRSS13 Q78 Colon 
TNRC6C N615 Colon 
TP53 R175 Colon 
TP53 R213 Colon 
TP53 R248 Colon 
TP53 R273 Colon 
TRRAP K159 Colon 
TTK R854 Colon 
TTLL11 A163 Colon 
TTN I2725 Colon 
TTN I2771 Colon 
TYSND1 L258 Colon 
UBR5 E2121 Colon 
UHRF1 P674 Colon 
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USP35 T411 Colon 
USP35 T655 Colon 
USP36 K959 Colon 
USP6 V148 Colon 
VEZT S74 Colon 
VPS13A R161 Colon 
VPS13A K372 Colon 
VSIG10L M356 Colon 
WDTC1 E290 Colon 
ZBTB42 R15 Colon 
ZDBF2 K1728 Colon 
ZNF233 L662 Colon 
ZNF365 K399 Colon 
ZNF516 V1037 Colon 
ZNF518A T929 Colon 
ZNF696 R341 Colon 
ZNF717 E818 Colon 
ZNF814 G320 Colon 
ZNF837 A242 Colon 
ZSCAN1 L54 Colon 
AGAP10 H228 Endometrium 
BCOR N1425 Endometrium 
BCOR N1459 Endometrium 
CTNNB1 S33 Endometrium 
CTNNB1 S37 Endometrium 
FBXW7 R465 Endometrium 
FGFR2 S252 Endometrium 
GTF2I N440 Endometrium 
KRAS G12 Endometrium 
KRAS G13 Endometrium 
MAX H28 Endometrium 
OR8I2 A270 Endometrium 
PIK3CA H1047 Endometrium 
PIK3CA G118 Endometrium 
PIK3CA E542 Endometrium 
PIK3CA E545 Endometrium 
PIK3CA Q546 Endometrium 
PIK3CA R88 Endometrium 
PIK3CA R93 Endometrium 
PPP2R1A P179 Endometrium 
PTEN R130 Endometrium 
RGPD3 L812 Endometrium 
RGPD3 R816 Endometrium 
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RP11-231C14.2 H27 Endometrium 
RSBN1L L432 Endometrium 
SPDYE3 S418 Endometrium 
TLK2 R262 Endometrium 
TMEM106B R140 Endometrium 
TP53 R248 Endometrium 
VIT G344 Endometrium 
ALK F1174 Head&Neck 
ALK R1275 Head&Neck 
ATP2B3 G272 Head&Neck 
BRD4 A467 Head&Neck 
CACNA1G S1109 Head&Neck 
CHD4 R1353 Head&Neck 
CHD4 P799 Head&Neck 
DDR1 I141 Head&Neck 
DMBT1 G158 Head&Neck 
DMBT1 S716 Head&Neck 
DNM1 G146 Head&Neck 
DOCK7 D185 Head&Neck 
ERBB2IP T1116 Head&Neck 
ERBB2IP S750 Head&Neck 
ERBB3 N101 Head&Neck 
ESR2 H115 Head&Neck 
FAM22D C197 Head&Neck 
FAM83A H119 Head&Neck 
FYB D285 Head&Neck 
HEATR8 N219 Head&Neck 
HEATR8 A701 Head&Neck 
HRAS G12 Head&Neck 
HRAS G13 Head&Neck 
HRAS Q61 Head&Neck 
MCMDC2 R369 Head&Neck 
MLST8 D181 Head&Neck 
NACAD P905 Head&Neck 
NFASC V258 Head&Neck 
NUTM2A C197 Head&Neck 
PIK3CA H1047 Head&Neck 
PIK3CA E542 Head&Neck 
PIK3CA E545 Head&Neck 
PTPRD V225 Head&Neck 
QKI D131 Head&Neck 
RP11-368J21.2 A454 Head&Neck 
SETDB1 F234 Head&Neck 
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SLMAP I195 Head&Neck 
TP53 R175 Head&Neck 
TP53 R196 Head&Neck 
TP53 R213 Head&Neck 
TP53 Y220 Head&Neck 
TP53 R248 Head&Neck 
TP53 R282 Head&Neck 
TTN R62 Head&Neck 
ABCA6 V801 Kidney 
ADAMTS10 R182 Kidney 
AHNAK P5445 Kidney 
APOBEC3H N15 Kidney 
ARHGEF5 E487 Kidney 
C22orf31 A261 Kidney 
C8orf45 Y111 Kidney 
CCKBR R396 Kidney 
CCKBR R465 Kidney 
CDH5 V141 Kidney 
CENPH K138 Kidney 
CHEK2 K373 Kidney 
COL5A3 P176 Kidney 
CUZD1 R355 Kidney 
DIEXF K229 Kidney 
F2RL2 C143 Kidney 
FCRLA L196 Kidney 
GBP6 K155 Kidney 
GCNT2 F107 Kidney 
GNLY L76 Kidney 
GOLGA6L10 A469 Kidney 
GPR158 K1027 Kidney 
IL34 N155 Kidney 
KIF6 D714 Kidney 
LILRB3 R143 Kidney 
LRRK2 I1294 Kidney 
MCCC2 A249 Kidney 
MED13 P1012 Kidney 
MLLT3 S167 Kidney 
N4BP2 G560 Kidney 
NIPBL N141 Kidney 
NUP155 P990 Kidney 
OPRK1 V380 Kidney 
OR11H4 P89 Kidney 
OR2B11 T244 Kidney 
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PIP4K2A R133 Kidney 
POTEB C221 Kidney 
PREX2 G233 Kidney 
PSKH2 G312 Kidney 
RFX3 I519 Kidney 
RNF213 S1184 Kidney 
RNF213 S3160 Kidney 
RP13-996F3.4 V159 Kidney 
RPL8 G153 Kidney 
RPS12 I94 Kidney 
RPS9 L25 Kidney 
RYBP G291 Kidney 
SCYL2 Q715 Kidney 
SEMA5B G44 Kidney 
SERPINA10 E64 Kidney 
SH3GL1 R184 Kidney 
SLC11A2 Y357 Kidney 
SLC2A5 P496 Kidney 
SLC36A2 G317 Kidney 
SRBD1 R464 Kidney 
SRGAP3 R559 Kidney 
TLK2 R262 Kidney 
TUBA3E A126 Kidney 
UBA7 L383 Kidney 
UBBP4 R73 Kidney 
UBE3C T888 Kidney 
UBE4A N800 Kidney 
UPF3A L91 Kidney 
XPNPEP1 S299 Kidney 
ZNF462 Q759 Kidney 
ZNF605 S82 Kidney 
ZNF776 V299 Kidney 
ACO1 S174 Liver 
AGAP3 G21 Liver 
AUTS2 L102 Liver 
CACNA1C T79 Liver 
CACNA1G Q767 Liver 
CFLAR I190 Liver 
CNOT4 A188 Liver 
COL6A2 G283 Liver 
CTNNB1 S45 Liver 
CTNNB1 T41 Liver 
CTNNB1 S33 Liver 
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CTNNB1 S37 Liver 
CTNNB1 G34 Liver 
DACT3 G278 Liver 
FGFR1 A21 Liver 
FUBP1 Y582 Liver 
HSPD1 R24 Liver 
HSPD1 G56 Liver 
KCNMA1 T254 Liver 
KIF4A R598 Liver 
MAGI1 Q410 Liver 
MAPK9 G35 Liver 
MBD1 G177 Liver 
NPM1 G90 Liver 
PCDH11X V38 Liver 
PIK3CA H1047 Liver 
SEC16A R280 Liver 
TMEM50B A139 Liver 
TMPRSS13 S70 Liver 
TP53 R249 Liver 
TP53 Y163 Liver 
TP53 G245 Liver 
TP53 R213 Liver 
TTN E155 Liver 
TTN S147 Liver 
TTN G156 Liver 
YEATS2 L316 Liver 
ZNF208 V325 Liver 
AGAP10 H228 Lung 
ATXN3 K295 Lung 
CD6 S52 Lung 
CHEK2 K373 Lung 
DSPP D881 Lung 
EGFR L858 Lung 
KRAS G12 Lung 
KRAS Q61 Lung 
KRT2 G104 Lung 
MUC6 S2085 Lung 
PIK3CA H1047 Lung 
PIK3CA E542 Lung 
PIK3CA E545 Lung 
PNKP P16 Lung 
RP11-671M22.1 R443 Lung 
RPSAP58 Q111 Lung 
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TP53 T125 Lung 
TP53 R158 Lung 
TP53 R248 Lung 
TP53 R249 Lung 
TP53 R273 Lung 
U2AF1 S34 Lung 
WASH3P G374 Lung 
ZNF814 S332 Lung 
ACSM3 G485 Myeloid 
AKIRIN2 Y201 Myeloid 
AKT3 K172 Myeloid 
ALPP D64 Myeloid 
ANGPTL4 Q143 Myeloid 
AP4B1 M100 Myeloid 
BRAF V600 Myeloid 
BZRAP1 S1417 Myeloid 
CALR K385 Myeloid 
CCND1 Y44 Myeloid 
CD79B Y196 Myeloid 
CLCN2 G715 Myeloid 
CNDP1 L20 Myeloid 
CXCL10 R93 Myeloid 
DCTN2 R181 Myeloid 
DNMT3A R882 Myeloid 
EIF3D A43 Myeloid 
EIF4G1 K643 Myeloid 
EZH2 Y602 Myeloid 
EZH2 Y646 Myeloid 
FLT3 D835 Myeloid 
GRN L46 Myeloid 
HLA-DRB1 H256 Myeloid 
IDH1 R132 Myeloid 
IDH2 R140 Myeloid 
JAK2 V617 Myeloid 
KRAS G12 Myeloid 
MICAL2 A388 Myeloid 
MPL W515 Myeloid 
MUC6 P1965 Myeloid 
MYD88 L265 Myeloid 
NEDD9 D178 Myeloid 
NEFH P655 Myeloid 
NIT1 R33 Myeloid 
NOTCH1 P2514 Myeloid 
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NPM1 W288 Myeloid 
NPR2 K683 Myeloid 
NRAS Q61 Myeloid 
NSMAF R850 Myeloid 
NSMAF R881 Myeloid 
ORM1 R86 Myeloid 
P4HA1 R118 Myeloid 
PARP4 A1096 Myeloid 
PEX6 V788 Myeloid 
PFKFB3 K147 Myeloid 
PKD1L2 N236 Myeloid 
PLIN4 A811 Myeloid 
PLIN4 A883 Myeloid 
PSME2 V17 Myeloid 
PSRC1 D7 Myeloid 
PYGM A610 Myeloid 
RECQL4 L1132 Myeloid 
RPE65 V287 Myeloid 
RPS16 V100 Myeloid 
SF3B1 K700 Myeloid 
SF3B1 G742 Myeloid 
SH3BP1 R229 Myeloid 
TP53 R248 Myeloid 
TUBA1B D76 Myeloid 
U2AF1 Q157 Myeloid 
U2AF1 S34 Myeloid 
USP3 E443 Myeloid 
XPO1 E571 Myeloid 
ZNF217 R629 Myeloid 
ZNF98 T451 Myeloid 
ABL1 S349 Ovarian 
ANKRD36C V306 Ovarian 
ARFIP1 Q373 Ovarian 
BAHD1 W653 Ovarian 
BEND5 S173 Ovarian 
BEND5 S342 Ovarian 
CDSN H260 Ovarian 
CEP152 G1415 Ovarian 
CHEK2 R519 Ovarian 
CHRNA5 T148 Ovarian 
CLASP1 A1272 Ovarian 
CNGA2 I524 Ovarian 
CYFIP2 D543 Ovarian 
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DDX23 R351 Ovarian 
DHX8 H768 Ovarian 
FCAMR T88 Ovarian 
FUBP1 G358 Ovarian 
HHLA2 V145 Ovarian 
KIAA0355 G168 Ovarian 
KLK2 Q39 Ovarian 
KRAS G12 Ovarian 
LRRC34 V374 Ovarian 
LRRIQ4 G151 Ovarian 
MYCBP2 S3024 Ovarian 
MYOF T92 Ovarian 
NFXL1 R815 Ovarian 
NOXA1 A300 Ovarian 
PEAR1 P62 Ovarian 
PKD1L2 N236 Ovarian 
PLEKHG6 G68 Ovarian 
POLDIP3 A94 Ovarian 
POLR1C V193 Ovarian 
PREX1 K872 Ovarian 
PTGER3 H314 Ovarian 
SCUBE3 P821 Ovarian 
SIK2 T878 Ovarian 
SI W1086 Ovarian 
TP53 Y103 Ovarian 
TP53 R175 Ovarian 
TP53 I195 Ovarian 
TP53 Y220 Ovarian 
TP53 N239 Ovarian 
TP53 R248 Ovarian 
TP53 R273 Ovarian 
WDR37 R303 Ovarian 
ZBBX L299 Ovarian 
ZFP112 H827 Ovarian 
ZFR2 P441 Ovarian 
ZNF510 T356 Ovarian 
ZYG11A N606 Ovarian 
ADRA1A R235 Pancreas 
ATP2B3 E151 Pancreas 
BMPR1A D414 Pancreas 
CACNA1C N348 Pancreas 
ERBB2IP R1037 Pancreas 
GALR3 L256 Pancreas 
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GNAS R201 Pancreas 
GNAS R844 Pancreas 
GRIA4 R368 Pancreas 
IFT43 L44 Pancreas 
KLKB1 I199 Pancreas 
KRAS G12 Pancreas 
KRAS Q61 Pancreas 
MSL2 S419 Pancreas 
NTM T166 Pancreas 
NTNG1 S289 Pancreas 
PCSK5 S487 Pancreas 
PRKCB G88 Pancreas 
SF3B1 K700 Pancreas 
SHPRH Q798 Pancreas 
SLC26A5 E30 Pancreas 
SLC8A3 D72 Pancreas 
TP53 R175 Pancreas 
TP53 C176 Pancreas 
TP53 R196 Pancreas 
TP53 R213 Pancreas 
TP53 G245 Pancreas 
TP53 R248 Pancreas 
TP53 R273 Pancreas 
TP53 R342 Pancreas 
TTN Q369 Pancreas 
USP20 V422 Pancreas 
AGAP10 H228 Prostate 
ENSG00000103472 W375 Prostate 
FAM129C G603 Prostate 
MCMDC2 T314 Prostate 
MED12 L1224 Prostate 
NBPF10 K3445 Prostate 
NCOA6 Q269 Prostate 
RGPD8 P1760 Prostate 
SPOP F133 Prostate 
SYT16 R131 Prostate 
UBBP4 L149 Prostate 
ZDHHC11 A303 Prostate 
ZNF91 R333 Prostate 
AGAP10 H228 Skin 
AGAP10 M293 Skin 
BRAF V600 Skin 
C15orf23 S24 Skin 
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CTAGE1 F739 Skin 
DDX11 R167 Skin 
DTNA R255 Skin 
IDH1 R132 Skin 
LEPR I740 Skin 
NLRP1 R698 Skin 
NRAS Q61 Skin 
PCDHGA1 R293 Skin 
RAC1 P29 Skin 
RGPD8 P1760 Skin 
RGS7 R44 Skin 
TP53 R213 Skin 
TRRAP S722 Skin 
WASH3P G374 Skin 
CNBD1 L396 Stomach 
ERBB3 V104 Stomach 
KRAS G12 Stomach 
KRAS G13 Stomach 
PGM5 I98 Stomach 
PIK3CA H1047 Stomach 
PIK3CA E542 Stomach 
PIK3CA E545 Stomach 
RIMS2 S231 Stomach 
TP53 R175 Stomach 
TP53 C176 Stomach 
TP53 R196 Stomach 
TP53 R213 Stomach 
TP53 G245 Stomach 
TP53 R248 Stomach 
TP53 R273 Stomach 
TP53 R282 Stomach 
ADRA1A A104 Thyroid 
BRAF V600 Thyroid 
CACNA1A H2219 Thyroid 
CBWD6 A154 Thyroid 
CLIP1 L271 Thyroid 
DIDO1 T580 Thyroid 
FBXW10 L261 Thyroid 
GOLGA8B A488 Thyroid 
HAVCR1 L34 Thyroid 
HRAS Q61 Thyroid 
KREMEN1 P4 Thyroid 
MAML3 Q491 Thyroid 
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MAML3 Q493 Thyroid 
MLL3 I882 Thyroid 
MUC16 P328 Thyroid 
MUC6 N1519 Thyroid 
NEFH E645 Thyroid 
NOTCH1 T349 Thyroid 
NRAS Q61 Thyroid 
OBSCN A998 Thyroid 
PI4KA P1714 Thyroid 
RAB11FIP3 A30 Thyroid 
RGPD8 P1121 Thyroid 
RP11-578F21.5 Q441 Thyroid 
SCN5A D1978 Thyroid 
TMPRSS13 S70 Thyroid 
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Table S3.6 A full list of the hotspot mutations that were highly prevalent in specific 
cancer types in TCGA 
 
 
Cancer_Type Gene aa_Pos Mut_Percent adj_Pvalue 
thca AGAP10 H228 2.80% 7.35E-04 
skcm AGAP10 M293 2.80% 1.62E-08 
brca AKT1 E17 2.30% 7.97E-09 
coadread APC R1114 2.70% 2.54E-06 
coadread APC R1450 8.40% 4.96E-22 
coadread APC R876 5.30% 4.01E-14 
ucec BCOR N1459 3.20% 7.14E-09 
stad BMPR2 N583 2.00% 1.49E-04 
thca BRAF V600 56.20% 3.31E-145 
skcm BRAF V600 37.80% 5.74E-49 
coadread BTNL8 V21 1.30% 9.06E-03 
skcm C15orf23 S24 2.80% 1.62E-08 
stad CCDC43 R216 2.00% 1.49E-04 
paad CD209 R129 8.60% 2.98E-04 
blca CD209 R129 4.00% 3.27E-04 
stad CNBD1 L396 2.00% 4.68E-04 
ucec CTNNB1 G34 2.00% 1.88E-04 
lgg DDX11 R167 2.90% 1.23E-03 
laml DNMT3A R882 14.90% 4.24E-38 
stad DOCK3 P1852 6.60% 2.47E-13 
coadread ERBB3 V104 2.20% 5.63E-04 
stad ESRP1 N512 3.30% 3.25E-07 
stad FAM18A F140 2.00% 1.49E-04 
coadread FBXW7 R465 5.30% 6.20E-09 
ucec FBXW7 R465 2.80% 9.17E-04 
ucec FGFR2 S252 3.60% 6.31E-11 
blca FGFR3 S249 4.00% 7.02E-05 
laml FLT3 D835 8.20% 1.94E-21 
brca GOLGA6L2 E537 0.90% 1.27E-04 
stad GTF2I N440 2.00% 1.49E-04 
hnsc HRAS G12 2.00% 1.36E-05 
thca HRAS Q61 3.70% 9.05E-10 
lgg IDH1 R132 76.60% 1.28E-169 
laml IDH1 R132 9.70% 8.35E-04 
coadread KRAS G12 29.80% 8.22E-39 
luad KRAS G12 22.90% 7.20E-24 
paad KRAS G12 57.10% 1.17E-17 
ucec KRAS G12 14.50% 1.24E-09 
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coadread KRAS G13 4.90% 4.80E-07 
ucec KRAS G13 3.60% 7.62E-05 
stad KRAS G13 3.90% 1.01E-03 
paad KRAS Q61 11.40% 3.44E-05 
brca MAGI1 Q421 0.80% 4.95E-04 
ucec MAX H28 1.60% 4.55E-05 
gbm NBPF10 E3455 2.10% 1.37E-03 
kirc NEFH P655 0.70% 2.16E-03 
laml NPM1 W288 25.60% 1.58E-69 
brca NR1H2 Q175 1.80% 2.44E-10 
coadread NRAS G12 2.70% 3.80E-04 
skcm NRAS Q61 23.60% 1.89E-44 
thca NRAS Q61 8.00% 7.74E-07 
skcm PCDHGA1 R293 2.00% 3.48E-06 
stad PGM5 I98 10.50% 5.36E-22 
brca PIK3CA E542 4.10% 5.20E-06 
ucec PIK3CA E542 5.20% 1.04E-03 
hnsc PIK3CA E542 4.60% 2.27E-03 
brca PIK3CA E545 6.50% 2.92E-06 
hnsc PIK3CA E545 6.80% 2.43E-03 
ucec PIK3CA G118 2.40% 1.97E-04 
brca PIK3CA H1047 15.40% 6.47E-53 
ucec PIK3CA H1047 8.00% 2.75E-03 
brca PIK3CA N345 1.70% 1.63E-04 
ucec PIK3CA Q546 4.40% 5.53E-07 
ucec PIK3CA R88 4.40% 4.50E-08 
ucec PIK3CA R93 2.40% 1.25E-06 
ucec PTEN R130 23.30% 1.09E-57 
skcm RAC1 P29 3.90% 2.25E-10 
skcm RGS7 R44 2.40% 2.87E-05 
hnsc RPSAP58 Q111 3.90% 5.20E-06 
blca RXRA S427 5.00% 4.26E-08 
brca SF3B1 K700 1.00% 1.08E-04 
blca SLAMF1 S277 3.00% 6.19E-04 
stad SLC3A2 K331 2.60% 3.15E-05 
coadread SMAD4 R361 3.10% 7.01E-05 
stad SMAD4 R361 3.90% 7.97E-05 
stad STAMBPL1 K405 2.00% 1.49E-04 
stad TAF1B N66 2.60% 7.88E-05 
blca TP53 E285 3.00% 2.96E-03 
brca TP53 G108 0.60% 5.97E-03 
ov TP53 G245 2.80% 6.70E-03 
ov TP53 I195 2.80% 1.27E-04 
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lusc TP53 R158 4.50% 4.48E-06 
coadread TP53 R175 7.60% 3.44E-07 
hnsc TP53 R213 2.90% 8.65E-03 
blca TP53 R248 10.00% 1.66E-04 
ov TP53 R248 5.40% 1.03E-03 
luad TP53 R249 3.00% 1.95E-04 
lgg TP53 R273 17.50% 2.64E-16 
ov TP53 R273 6.60% 2.30E-04 
ov TP53 Y220 3.50% 1.28E-04 
skcm TRRAP S722 1.60% 4.83E-05 
laml U2AF1 S34 3.60% 7.26E-06 
luad U2AF1 S34 2.20% 1.89E-03 
thca UBBP4 L149 2.20% 6.23E-03 
stad UBR5 E2121 5.30% 1.72E-10 
brca USP36 K959 1.30% 2.17E-05 
stad ZNF365 K399 2.00% 1.49E-04 
gbm ZNF814 D404 3.10% 7.15E-05 
blca ZNF814 D404 4.00% 5.27E-03 
paad ZNF91 R333 14.30% 1.31E-07 
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